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Liver cysts are a quite common manifestation in the general population with an 
incidence of 5-20%.1-3 In most cases, cysts are small and do not lead to symptoms. 
In a limited number of patients, the liver cyst grows larger than 7 cm and causes 
symptoms due to compression of adjacent structures. Treatment of the cyst in these 
instances may lead to relief of symptoms.
The appearance of multiple fluid-filled cysts scattered throughout the whole liver 
parenchyma is termed a “polycystic liver”. It was first describe by Bristowe4 in 1856. 
Polycystic livers are rare and a number of autopsy studies give a prevalence of 0.13­
0.52% in the general population.5;6
Polycystic livers are associated with two inherited diseases: autosomal dominant 
polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver 
disease (PCLD) (Figure 1.1). Although the genetic background is different in these 
two diseases, the pathogenesis leading to hepatic cysts is probably similar.7 This 
introduction will first address the phenotype of PCLD and ADPKD followed by a 
description of some elements of polycystic livers.
Figure 1.1 Polycystic livers on com puted tom ography (CT)
(A) a po lycystic  liver an d  po lycystic  k idneys in a p a tie n t  w ith  a u to so m a l d o m in a n t po lycystic  k idney  d isease  
(ADPKD) an d  (B) a po lycystic  liver in a p a tie n t  w ith  po lycystic  liver d ise a se  (PCLD). L liver, K kidneys.
POLYCYSTIC LIVER DISEASE ( P C L D )
PCLD differs from ADPKD on the fact that polycystic kidneys are absent (Figure 
1.1B). The occurrence of PCLD as an independent disease from ADPKD has been 
suggested for a very long time.6;8 In 1952, an autopsy study gave a first indication that 
polycystic livers could occur in an isolated form. The authors found that 8 out of 24 
patients had a polycystic liver without polycystic kidneys.8 In 1979, a first family was 
identified with a polycystic liver without renal abnormalities9 and in 1982, a second
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family was identified.10 Genetic analysis of families with an isolated polycystic liver 
showed that these families were unlinked to PKD1 and PKD2, the genes involved 
in ADPKD.11;12 In 2003 and 2004, two genes associated with isolated polycystic 
liver disease PRKCSH  and SEC63.13-15 The corresponding protein products are 
hepatocystin for PRKCSH  and Sec63p for SEC63.
Kidney cysts can be present in PCLD patients, but in most instances these are limited 
to only one or two. Although, this could be biased, as in most studies PCLD is 
only diagnosed when patients have less than 5 kidney cysts and/or do not fulfill the 
Ravine criteria for ADPKD.16
Other extrahepatic manifestations may be involved, although information is scarce. 
There is an indication that mitral valve abnormalities are more common in PCLD 
patients compared with their unaffected relatives. In addition, it is not clear whether 
intracranial aneurysms or dissection occur at a higher prevalence in PCLD.7
AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (A D P K D )
ADPKD is the third most common disease worldwide and the most common inherited 
renal disease. The incidence is 1:400-1000 in the Western population.17;18 The disease 
is inherited in an autosomal dominant fashion, and is caused by mutations in PKD1 in 
85% of the cases and in PKD2 in the remaining 15% of the cases.19 The corresponding 
protein products are polycystin-1 for PKD1 and polycystin-2 for PKD2. However, 
families with ADPKD unlinked to either one of the known loci suggest the presence 
of a third ADPKD gene.20 Primarily, the disease is characterized by the progressive, 
bilateral development and enlargement of focal cysts in the kidneys. Most cysts 
arise from the collecting duct, but some may arise from other tubular segments.21-23 
Ultimately, the enlargement of focal renal cysts results in end-stage renal disease 
in most patients with PKD1 mutations and in more than 50% of the patients with 
PKD2 mutations.24’25 Five percent o f patients requiring renal replacement therapy 
have ADPKD.24 Total kidney volume and cyst volumes increase exponentially with 
age.26 The average growth is 5.27% per year, but there is a wide range of variability.27 
Compared with individuals affected by PKD2, those with PKD1 have more severe 
disease: younger age at presentation, more cysts and larger kidneys, higher prevalence 
of hypertension and younger age at time of end-stage renal disease.19’26 As there is no 
difference in growth rate between ADPKD caused by either PKD1 or PKD2, cyst 
initiation but not cyst enlargement is modulated by the disease gene. Clinically, there 
appears to be a difference in overall and renal survival between patients with a PKD1 
or PKD2 mutation, but neither PKD1 or PKD2 are benign diseases as both have 
a deleterious impact on overall life expectancy. However important, identification 
of the mutated gene at the individual patient level is not currently possible in the
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majority of cases, because of the technical demands and expense of both mutation 
detection and linkage analysis in ADPKD.19
The diagnosis of ADPKD in patients with a family history is based on imaging 
techniques.16 Because of the low costs and safety, renal ultrasonography (US) is 
commonly used. Sonographic diagnostic criteria for individuals at 50% risk for the 
disease of PKD1 include at least two unilateral or bilateral cysts in individuals younger 
than 30 years; two cysts in each kidney in individuals 30-59 years; and four cysts in 
each kidney in individuals 60 years or older (Table 1.1).16 The sensitivity of these criteria 
is nearly 100% in these patients. In contrast, the sensitivity of these criteria is only 
67% for individuals with PKD2 mutations younger than 30 years.28 Recently, more 
stringent criteria have been developed to evaluate at-risk individuals from ADPKD 
families of unknown genotype. The presence of at least three (uni- or bilateral) renal 
cysts in patients aged 15-39 years and two cysts in each kidney in patients aged 40-59 
years can be regarded as sufficient for diagnosis. For at-risk individuals 60 years and 
older, the criterion of more than four cysts in each kidney is required for diagnosis.29
Table 1.1 Ultrasonographic diagnostic criteria for ADPKD in at-risk individuals from 
families with a m utation in either PKD1 or PKD2
Age group (years) PKD1 PKD2
15—30 > 2 cysts uni- or bilateral
15—39 > 3 cysts uni- or bilateral
30-59 > 2 cysts bilateral
40-59 > 2 cysts bilateral
>60 > 4 bilateral > 4 bilateral
Typical presenting symptoms in ADPKD are linked to the presence of renal cysts 
and subsequent vascular complications and include flank pain, hematuria, renal colics, 
urinary tract infections and hypertension.
Hypertension is the most common manifestation in ADPKD and is present in about 
50% of patients aged 20-34 years with normal renal function. The diagnosis of 
hypertension is often made at a late stage, and nearly 100% of patients with end-stage 
renal disease have hypertension.30-32 In most patients, renal function is maintained 
until the fourth to sixth decade of life. The development of renal failure is highly 
variable. Glomerular filtration rate remains constant for many years. It only declines 
relatively late in the course of the disease, when mechanical compression of normal 
renal tissue by cysts occurs.33 Then, the kidneys are substantially enlarged and distorted
12 | Chapter 1
with little recognizable parenchyma on imaging studies. Risk factors for renal failure 
include male sex, especially in ADPKD caused by PKD2 mutations, black race, first 
episode of hematuria before 30 years of age, onset o f hypertension before age of 35 
years, hyperlipidemia, low HDL cholesterol concentrations and sickle cell trait.19’34-36 
In addition, there is a significant correlation between increase of renal volume and 
the change in glomerular filtration rate in both men and women.37 
Several extrarenal manifestations are associated with ADPKD. Though less common, 
cysts can arise at other sites: 40% of the male patients present cysts in the seminal 
vesicles and 5% and 8% of the patients have cysts in the pancreas and arachnoid 
membrane, respectively. Ovarian cysts are not associated with ADPKD.
In 6% of patients without and 16% of patients with a positive family history, 
intracranial aneurysms occur. In ADPKD, intracranial aneurysms are approximately 
five times more common than in the general population.26 As most patients do not 
experience symptoms from an aneurysm, widespread screening is not indicated. It 
yields mostly small aneurysms with a low risk of rupture. Instead, it has been advised 
to direct screening to ADPKD patients with a positive family history for cerebral 
aneursyms.
In up to 25% of patients with ADPKD, mitral valve prolapse is found on 
echocardiography.38-40 Aortic insufficiency can occur in association with dilatation of 
the aortic root. With time, the lesions progress, but they rarely need valve replacement 
therapy.
Finally, the most common extrarenal manifestation in ADPKD is a polycystic liver 
(Figure 1.1A). The prevalence of polycystic livers in ADPKD patients is 58% in 15­
24 year olds, 85% in 25-34 year olds, and 94% in 35-46 year old patients.41 In an 
unknown number of patients with ADPKD, the polycystic liver is the major cause of 
symptoms, rather than the polycystic kidneys.
Treatment of polycystic kidneys is directed towards reducing morbidity and mortality 
due to the complications of the disease. Treatment of hypertension is one of the 
first steps in dealing with ADPKD. Other efforts have been directed towards the 
treatment of renal cystogenesis and renal cyst growth because this is the root of the 
problem in ADPKD.
Better understanding of the pathophysiology and the availability of animal models 
has enabled the development of preclinical trials and the identification of promising 
candidate drugs for clinical trials in the treatment of polycystic kidneys. One of 
the newly identified targets is 3’-5’-cyclic adenosine monophosphate (cAMP). The 
role o f intracellular cAMP is important as a second messenger in the development 
of cysts in the kidney and thereby kidney enlargement and renal dysfunction.42 By 
activation of adenylate cyclase, adenosine triphosphate (ATP) will be converted to 
cAMP. Enhanced cAMP is mediated via cAMP effector proteins Protein Kinase 
A (PKA) and Exchange Protein directly Activated by cAMP (EPAC) (Figure
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1.2).43 Vasopressin V2 receptor antagonists, such as tolvaptan, reduces intracellular 
cAMP concentrations and inhibits cyst development in a polycystic kidney (PCK) 
rat. However, these drugs have no effect on liver cysts, because of the absence of 
vasopressin V2 receptors on cholangiocytes.44 The antidiuretic hormone, arginine 
vasopressin (AVP), stimulates formation of cAMP. High water intake by itself will 
decrease plasma AVP concentrations and suppress the action of cAMP on the 
renal cysts.45 Somatostatin reduces the concentration of cAMP as well. An Italian 
pilot study demonstrated that six month treatment with octreotide, a somatostatin 
analogue, slowed kidney growth with 60%.46
Figure 1.2 Schematic overview of the  pathway involved in cell proliferation and 
fluid secretion of cystic epithelial cells in polycystic livers and kidneys
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P o ly c y s t ic  l iv e r  in  b o t h  P C L D  a n d  A D P K D
Liver cyst formation and growth
Liver cysts develop from embryonic ductal plate malformations on the level of the 
intralobular bile ductules.47 During life, these malformations, or Von Meyenburg 
complexes, evolve through overgrowth and subsequent dilatation into cysts that have 
lost their continuity with the biliary tree.7;48 It is unknown what exactly drives cyst 
formation.
The natural history of the disease suggests a continuous growth. The number and size 
of cysts increase with age and the disease typically becomes apparent at the fourth 
decade of life.17 The growth of individual cyst volume ranges from 0.25 mL to 22.8 
mL in twenty years.41 Women are more likely to develop a massive polycystic liver (>15 
cysts) and have larger maximal cyst compared with men. Female steroid hormones 
are associated with this more dominant character of the disease in women: pregnancy 
and the number of pregnancies are correlated with a more severe phenotype,49 and the 
use of estrogen treatment in postmenopausal women is associated with an increased 
liver volume.50
The development and growth of cysts are promoted by enhanced fluid secretion, 
extracellular matrix remodeling and hyperproliferation of the lining epithelial cells.18 
Several pathways are probably involved in cyst growth modulation.
One of the pathways is via cAMP, a second messenger in the intracellular signal 
transduction of the biliary epithelial cell. It stimulates secretion and proliferation 
in the same way as is described for kidney cysts.43;51;52 It has been demonstrated that 
secretin is one of the stimulators of adenylate cyclase, which activates the conversion 
of ATP to cAMP and results in cyst expansion.53 In ADPKD rodent models, elevated 
intracellular cAMP levels are associated with biliary epithelial cell hyperproliferation 
and cyst expansion.54 In line, human liver cyst fluid contains a very high concentration 
of cAMP. Further, vascular endothelium growth factor, several electrolytes and 
serum proteins were found in cyst fluid.55-57
Clinical presentation
The majority of persons with a polycystic liver do not have symptoms. It is not clear 
at what moment of the cyst development symptoms arise. Also, the course of the 
disease is unsure and unpredictable. Symptoms may arise due to the enlarged liver or 
cysts that compress other structures. Abdominal distension, early satiety, shortness of 
breath, dyspepsia and pain are most reported symptoms.7’17’58-60 Furthermore, patients 
could be restricted in their daily activities. Complications from the liver cysts, such as 
cyst hemorrhage, rupture and infection, portal hypertension and vena cava inferior 
compression, are not very common.17’58-60 There are some case-reports that describe 
very rare complications from polycystic livers, such as heart compression due to a
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large liver cyst and a pregnancy which was complicated by the polycystic liver.61-63 
Importantly, the complications are sometimes difficult to manage and need a broad 
expertise of the treating doctors. At physical examination an enlarged liver and 
sometimes individual cysts are palpable. In ADPKD patients, the kidneys may be 
palpable as well.
Laboratory results
The parenchymal liver volume of polycystic livers remains constant over an extreme 
range of cyst volumes.64 Moreover, the synthesis capacity is not disturbed. Serum 
concentrations of aspartate transferase (AST) and alanine transferase (ALT) and 
bilirubin are normal.59 Furthermore, patients do not have coagulation problems 
related to hepatic insufficiency. In contrast, serum concentrations of alkaline 
phosphatase and especially y glutamyl transferase can be elevated.7’59’60 Compression 
of cysts on the small bile ducts may be the cause of this elevation.
Elevated carbohydrate antigen 19-9 (CA19-9) in serum is found in 45% of patients 
with a polycystic liver. In cyst fluid, CA19-9 is extremely elevated and the expression 
of CA19-9 in the epithelial cyst lining is high. Moreover, serum CA19-9 levels are 
correlated with polycystic liver volume. As a consequence, elevation of serum CA19-9 
levels in patients with liver cysts is probably due to production and secretion of this 
compound by local cyst epithelia and leakage into the circulation.57 In addition, once 
CA19-9 is elevated, it remains elevated.65
D iagnosis
The diagnostic tools for a polycystic liver are several imaging modalities. The 
widespread use of ultrasonography (US), computed tomography (CT) and magnetic 
resonance imaging (MRI) in the evaluation of abdominal complaints, has made the 
discovery of hepatic cysts more frequently. There is no agreement in literature about 
the exact number of cysts for the definition of a polycystic liver, but definitions
mention a range from more than 10 or 20.58’66-68
Treatment
Treatment of the polycystic liver is performed in symptomatic patients and is palliative 
in nature. The aim of treatment is to reduce liver volume. Whether a patient is suitable 
for a therapeutic option, depends on the size and location of the liver cysts and the 
size of the liver itself. Furthermore, the expertise of the treating physician is of great 
importance in the result o f the treatment.
There is a lack of understanding how to select patients for the different therapeutic 
options and there is lack of an overview in the literature. Therefore, there is a Call for 
a Yielding Single Treatment Strategy for polycystic livers.
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The main aim of this thesis was to evaluate the available therapeutic options for 
polycystic livers and to identify new options.
The first part o f this thesis ‘Phenotypepresents the characterization of PCLD, 
polycystic liver disease without renal involvement (chapter 2). The second part 
o f the thesis ‘Invasive therapeutic options’, focuses on the results of current available 
invasive therapeutic options and in particular, aspiration-sclerotherapy (chapter 3), 
laparoscopic fenestration (chapter 4), hepatic resection (chapter 5) and the outcome 
of liver transplantation (chapter 6).
The third part ‘Non-invasive therapeutic options’, describes the results of new treatment 
strategies: in chapter 7 a case-report o f two patients treated with somatostatin- 
analogues, in chapter 8 a case series of patients treated with octreotide and in chapter 
9 a randomized, double blind, placebo-controlled trial with lanreotide.
The last part ‘Callfor a Yielding Single Treatment Strategy’, gives in chapter 10 an 
overview of the invasive therapeutic options and a suggestion for a treatment strategy. 
Furthermore, it describes opportunities for non-invasive therapeutic options. 
Chapters 11 and 12 summarize this thesis and give future perspectives regarding 
treatment of polycystic livers.
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Isolated polycystic liver disease (PCLD) is characterized by the presence of 
multiple cysts in the liver in absence o f polycystic kidneys. T he clinical profile 
of PCLD is poorly defined and we set out a study for the clinical characteristics 
of PCLD. We collected clinical data on 188 PCLD patients (defined as >10 
liver cysts) from five tertiary referral centers and 137 patients were selected  
for the purpose o f this study. We performed molecular analysis o f the PCLD  
associated genes PRKCSH and SEC63 in 91 patients. A total o f 118 (86%) 
patients were female. T he majority of patients (88%) had >20 cysts. M edian age 
at diagnosis was 47 years (range 23—84). 37 (41%) patients carried a mutation. 
Clinical symptoms at presentation were present in 111 (84%) patients. GGT 
was elevated to 1.4 tim es U L N  (IQR 1.0—2.7). Presence of a mutation and 
female gender predicted a more severe course: female patients were 9 years 
younger at tim e o f diagnosis (47 years; range 23—84) and 91% had symptoms 
(p<0.01); likewise, mutation carriers were younger at presentation (39 years; 
range 35—48) and 95% of this cohort had sym ptoms (p<0.01). D uring follow- 
up, 10% of untreated and 51% of treated patients developed complications. 
Mortality in this cohort was 8%, but only 2% died of PCLD-related causes. 
58% of patients were treated; a m edian of 2 years (range 0—25) after diagnosis. 
Conclusion: Symptomatic PCLD patients are m ainly females. Females and 
mutation carriers were younger at diagnosis and have a more severe course of 
disease.
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Polycystic livers are characterized by multiple fluid filled cysts scattered throughout the 
liver parenchyma. They are not very common: autopsy studies indicate a prevalence 
of 0.05 to 0.530/o.1 In the majority of patients, polycystic livers are associated with 
the genetic disorder autosomal dominant polycystic kidney disease (ADPKD), 
where polycystic kidneys are the primary phenotype. On the other hand, polycystic 
livers can also arise in the absence of polycystic kidneys and is then termed isolated 
polycystic liver disease (PCLD).1-6 This disorder is much less frequent than ADPKD 
and incidence or prevalence rates are currently unknown.1
For a long time, PCLD was thought to be a phenotypic variant of ADPKD.7 The 
finding of isolated polycystic livers in autopsy studies and the identification of whole 
families with dominantly inherited polycystic livers, caused a paradigm shift in this 
concept.1-4’8 Indeed, the discovery of mutations in two genes, PRKCSH  and SEC63, 
confirmed that PCLD is a disorder distinct from ADPKD.6’9-11 
For ADPKD, the clinical course, treatment options and value of screening have been 
studied well.12-17 In contrast, the clinical profile of PCLD is poorly defined and only 
few small studies report on the effect o f surgical therapies.17-21
Therefore, we decided to collect clinical, radiological and laboratory data from these 
patients in order to obtain a comprehensive clinical characterization of PCLD.
P a t ie n t s  a n d  Me t h o d s
In November 2004 we issued a national call for PCLD patients via the Dutch Society 
of Hepatology and between November 2005 and September 2008 we retrospectively 
constructed a large clinical database. We recruited index patients from five tertiary 
referral hospitals, of which 3 Dutch and one Belgian liver transplant centers. Selection 
of PCLD patients prior to inclusion was made by attending hepatologists from 
participating centers. As such we were able to include the majority of these patients 
from the Netherlands.
We reviewed the medical records and abdominal imaging (ultrasonography, and 
computed tomography (CT) scans) studies of recruited patients. Abdominal imaging 
was performed as part o f routine clinical care. In case of uncertainty of the number 
of cysts, the investigators reassessed the abdominal studies. The data set consisted 
of patient demographics, symptoms and laboratory findings specific to PCLD taken 
from published reports on PCLD and ADPKD.11’17’18’22’23 We collected data, at time of 
diagnosis or first visit to the clinic, concerning age, date of diagnosis, relevant medical 
history, family history, total of cysts, diameter of largest cyst (in cm), symptoms, 
laboratory results and estrogen exposure. Complications (including cyst hemorrhage,
Intro d uctio n
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infection or rupture, portal hypertension, ascites, esophageal varices and inferior 
caval vein compression) and therapies (including aspiration, aspiration-sclerotherapy, 
open and laparoscopic fenestration, hepatic resection and liver transplantation) were 
assessed during the total follow-up period. PCLD patients were only included in our 
descriptive analyses if more than 10 cysts in the liver were present on abdominal 
imaging and who did not meet the Ravine criteria.24 Lastly, we included only index 
patients.
A total o f 188 patients were recruited, and based on the above mentioned criteria, 
137 patients were selected for the purpose of this study: 14 patients were excluded 
because they had fewer than 10 cysts’ ADPKD could not be ruled out in 23 patients 
as they met the ultrasonographic Ravine criteria’24 12 patients were excluded because 
of incomplete data and 2 patients because the diagnosis was adenoma.
In addition to data retrieved from medical files, Dutch patients were requested 
to fill in a questionnaire, which included questions on date of diagnosis, type and 
number of treatments received, family history, and estrogen exposure. As estrogen 
exposure is not routinely registered in medical records, we relied on results from the 
questionnaire. The questionnaire was also used to determine self-reported symptoms 
on abdominal pain, dyspnoea, dyspepsia, anorexia, and abdominal distension. We 
mailed a total of 88 questionnaires and 68 responses could be used for final analysis. 
Mutation analysis was carried out after informed consent from all individuals. We 
obtained blood samples from 91 patients. DNA was isolated following standard 
protocols. The complete coding region of the PRKCSH  and SEC63 genes was 
amplified by polymerase chain reactions and mutation detection was done following 
methods reported earlier.25
Approval for this study was obtained by the Medical Ethical Committee of the 
Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Statistical analysis
We performed several descriptive statistical analyses. Frequency tables were provided 
and numerical variables were presented as percentages’ continuous variables as 
median with range. We used the Pearson Chi-square test and the Wilcoxon test to 
compare differences between gender, patients with mutation or wildtype patients, 
symptomatic and asymptomatic patients and patients with or without indication 
for liver transplantation. Kaplan-Meier analysis was performed to calculate time 
to treatment. Laboratory results of alanine transferase (ALT), alkaline phosphatase 
(AP) and y glutamyl transferase (GGT), were compared to the upper limit of normal 
(ULN).
Data were analyzed using SPSS statistical software package version 16.0 (SPSS Inc., 
Chicago, IL, USA). A p-value of <0.05 was considered as statistically significant.
Clinical characterization o f PCLD | 27
Population characteristics at tim e of diagnosis
We included 137 index patients (111 Dutch and 26 Belgian). The large majority 
was female (118; 86%). Likewise, 121 (88%) patients had more than 20 cysts and 
the median diameter of the largest cyst was 9 cm (range 1—20). The median age at 
diagnosis was 47.3 years (range 23—84) (Table 2.1). Renal cysts were detected in 46 
(35%) patients. None of the patients had more than 2 renal cysts on either site.
R esu lt s
Table 2.1 Population characteristics at tim e of diagnosis
n /N *  (%)
Female 118/137 (86)
Median age at diagnosis in years (range) 47 (23-84)
Occurrence of pregnancy 91/102 (89)
Use of oral anticonceptives 76/83 (92)
Occurrence of mutation 37/91 (41)
Mutation in PRKCSH 30/91 (33)
Mutation in SEC63 8/91 (9)
Diagnosis at random abdominal screening 17/126 (14)
Cysts
>20 cysts 121/137 (88)
Median diameter of largest cyst in cm (range) 9 (1-20)
Kidney cyst(s) 46/135 (34)
Symptoms
Occurrence of symptoms 111/132 (84)
Abdominal pain 65/117 (56)
Abdominal distension 54/118 (46)
Dyspepsia 49/137 (36)
Dyspnea 35/137 (26)
Laboratory results
Median creatinine in ^mol/L (IQR) 72 (65-84)
Median AST in U /L (IQR) 20 (15-29)
Median ALT times ULN (IQR) 1.0 (1.0-1.0)
Median AP times ULN (IQR) 1.0 (1.0-1.0)
Median GGT times ULN (IQR) 1.4 (1.0-2.7)
Median bilirubin in ^mol/L (IQR) 8 (5-12)
* D e n o m in a to rs  is to ta l o f  p a tie n ts
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From the cohort of female patients, 102 (89%) had been pregnant with a median of 
2 pregnancies (range 1—11) and 83 (92%) used oral anticonceptives with a median 
duration of 12 years (range 1—41).
Mutational analysis was performed in 91 patients and in 37 (41%) patients a pathogenic 
mutation was found: 30 (33%) patients had a mutation in PRKCSH, and a mutation 
in SEC63 was found in 8 (9%) patients. One patient was double mutant: she had a 
mutation in PRKCSH  as well as in SEC63. In 17 (14%) patients the polycystic liver was 
discovered at random abdominal screening and 111 (84%) patients were symptomatic 
at first clinical presentation. The most common symptoms were abdominal pain in 
65 (56%) patients and abdominal distension in 54 (46%) patients.
Laboratory results were normal except for GGT, which was 1.4 times ULN (IQR 
1.0—2.7). While median AP levels for the complete PCLD cohort were normal, we 
found that they were elevated in a subset of 23 (17%) patients (median 1.8 times ULN 
(IQR 1.3—2.5)). GGT was elevated in 70 (51%) patients with median 2.5 times ULN 
(IQR 1.8—5.7). All patients with an elevated AP had elevated GGT levels as well. 
There were striking gender related differences in clinical presentation at diagnosis. 
Female patients were 9 years younger at time of diagnosis (47 years (range 23—84)) 
compared to males (56 years (range 36—78); p<0.01). In 47% of the female patients a 
mutation was found, while this was only the case for 7% of the male patients (^<0.01). 
The majority of female patients was symptomatic (91%), while less than half o f the 
males (42%) were symptomatic (p<0.01) (Figure 2.1A). Some 53% of the male patients 
were diagnosed at random abdominal screening, compared to only 7% of the female 
patients. Finally, more females had >20 cysts compared to the males from our cohort 
(92% versus 68%). In addition, females had larger cysts (median 10 cm (range 1—20)) 
than males (median 7 cm (range 1—20)). Along the same line, PCLD patients who 
had been pregnant had larger median cyst diameter (10 cm (range 2—20)) compared 
to those who had not been pregnant (7 cm (range 1—14)). We did not observe other 
effects of pregnancy on the phenotype of PCLD.
Patients with a PRKCSH  or SEC63 mutation had a more severe presentation at time 
of diagnosis. They were much younger at presentation (39 years (range 23—60)) 
compared to wildtype patients (54 years (range 34—80); p<0.01). Furthermore, 95% 
of the mutation carriers had clinical symptoms, whilst this was the case in only 70% 
of wildtype patients (p<0.01) (Figure 2.1B). Patients with a mutation had higher 
GGT levels (median 1.8 times ULN (IQR 1.0—2.7)) compared with patients without 
a mutation (median 1.0 times ULN (IQR 1.0—1.8)). All patients with a mutation had 
more than 20 cysts, but there was no difference in cyst size (both groups median 
9 cm). Finally, 6 patients with a mutation were listed for LT (liver transplantation), 
compared with 1 wildtype patient (p=0.01).
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Figure 2.1 Percentage of patients with symptoms
P e rc e n ta g e  is g iven  for all p a tie n ts . In p an el A for m a le  an d  fe m a le  p a tie n ts ;  in p an e l B for p a tie n ts  w ith  a 
m u ta tio n  an d  w ild ty p e  p a tien ts .
The most important differences between symptomatic and non-symptomatic patients 
were age at diagnosis (median 46 years (range 25—84) versus 60 years (23—78); p<0.01) 
and size of largest cyst (median 10 cm (range 1—20) versus 5 cm (range 1—20)). In 
general, the presence of symptoms was not related to the number of cysts.
Complications and Survival
The median follow-up period was 8.2 years (range 0—35). Six of the 60 untreated 
patients (3/6 patients were listed for LT) developed a complication: 5 (8%) patients 
had a cyst bleeding, 2 (3%) had portal hypertension, 1 (2%) had ascites and in 1 (2%) 
patient there was inferior caval vein compression (Table 2.2).
In the total cohort 9 (8%) patients (3 male, 6 female) died at a median age of 56 
years (range 44—86). Their median age at diagnosis was 45 years (range 36—77). Six 
patients were treated, with a median time of 4 years (range 0—11) after diagnosis. 
Three patients (33%) died after onset o f treatment related complications: one after 
open fenestration, one after hepatic resection and one during LT. The remaining 6 
patients died because of other reasons, unrelated to the liver cysts.
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Table 2.2 Complications
Complication Untreated (%) Treated (%)
Occurrence of complications 6 (10) 33 (51)
Cyst hemorrhage 5 (8) 15 (20)
Cyst infection 0 (0) 8 (12)
Cyst rupture 0 (0) 6 (9)
Portal hypertension 2 (3) 5 (9)
Ascites 1 (2) 5 (8)
Esophageal varices 0 (0) 2 (3)
Inferior caval vein compression 1 (2) 3 (5)
Treatment
During the follow-up period 79 (58%) patients were treated or awaited LT and all had 
severe clinical symptoms. After diagnosis, the median duration to first treatment was 
2.0 years (range 0-25) (Figure 2.2). The median age at treatment was 49 years (range 
27-81). Median duration to first time to use of one of either possible therapeutic option 
are shown in Table 2.3. The median total of treatments that a patient underwent was 
2 (range 1-25). A total of 44 (55.7%) patients needed more than one treatment during 
the time of follow-up. During the first year after diagnosis 22% of the patients were 
treated, but this increased to 44% after 5 years.
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Figure2.2 Duration until treatm ent after diagnosis of PCLD
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Table 2.3 Total of patients treated and total of sessions performed
N o of 
patients
N o of 
sessions
Median time from diagnosis to 
1st treatm ent in years (range)
Aspiration 23 51 1.0 (0-11)
Aspiration-sclerotherapy 39 72 3.0 (0-25)
Open fenestration 14 16 2.4 (0-9)
Laparoscopic fenestration 24 28 1.4 (0-13)
Hepatic resection 9 9 3.3 (0-15)
Liver transplantation 11 11 9.0 (2-15)
Complete data upon complications was available for 65 patients. O f these 65 patients, 
a total of 33 patients (51%) developed a complication and 11 patients had more than 
one complication. Cyst hemorrhage was seen in 15 (20%), cyst infection in 8 (12%), 
cyst rupture in 6 (9%), portal hypertension 5 (9%), ascites in 5 (8%), esophageal 
varices in 2 (3%) and inferior caval vein compression in 3 (5%).
Eleven patients (1M, 10F) underwent LT and five more patients (all female) are 
currently listed. These 16 (14%) patients had a median age at diagnosis of 41 years 
(range 29—67), which is 7 years younger than patients without indication (48 years 
(range 23—84)). There was no difference in cyst size between patients listed for LT 
and those who are not. More patients with an indication for LT had elevated GGT 
levels (81% versus 55%) and elevated AP levels (44% versus 16%), than those who did 
not. Seven (44%) patients had at least one previous treatment prior to LT: aspiration 
(n=2), aspiration-sclerotherapy (n=3), open (n=3) and laparoscopic fenestration (n=3) 
and hepatic resection (n=1). Indications for LT varied from mechanical difficulties 
in 44%, invalidation in 38%, pain in 19% and untreatable complications in 13%. The 
median age of the 11 patients who underwent LT is 52 years (range 40—65). In total, 
there were 3 intra-operative complications: in one female patient the transplantation 
procedure was prematurely terminated, because of the complicated explantation of 
the polycystic liver due to adhesions from several previous open fenestrations. In 
another patient there were problems with the vascularisation and one female patient 
died peri-operatively. Post-operative complications occurred in 55% of the patients 
and included acute rejection in 4 patients, infection in 1, vascular problems in 2 and 3 
patients had miscellaneous problems. There was no graft failure and no death during 
follow-up.
32 | Chapter 2
D iscu ssio n
This study describes the largest series of index PCLD patients, mainly including 
symptomatic patients, reported so far and allows us to identify risk factors for 
an adverse clinical course. We found that females and patients with a pathogenic 
PRKCSH  or SEC63 mutation have more symptoms, are younger at presentation, and 
are more likely to be listed for a LT. Given the size of this cohort, we estimate that the 
prevalence of PCLD in the adherence region is 1 per 158 000 (www.cbs.nl).
In order to obtain an accurate overview of PCLD, we chose the arbitrary number of 
>10 hepatic cysts and followed the Ravine criteria to exclude ADPKD patients.24 The 
Ravine criteria are formulated to diagnose ADPKD in relatives of ADPKD patients 
with a pathogenic PKD1 mutation. We found that 34% of patients had renal cysts, 
which is comparable to the prevalence in healthy adults.26 One should bear in mind 
that we excluded patients when they had numerous renal cysts, including 3 patients 
who carried a PCLD associated mutation. Thus, although our data do not allow us to 
judge whether or not renal cysts are part o f the PCLD phenotype, its presence does 
not exclude PCLD.
In ADPKD there appears to be a gender related dichotomy between renal and liver 
symptoms: males have a more severe course of renal disease, while females are more 
likely to suffer from a polycystic liver.27 Apart from the known risk factors for a 
severe clinical course, such as number of pregnancies and use of estrogens, no other 
factors are known. We did not observe other symptoms or complications on PCLD 
apart from those reported in ADPKD patients.28’29 Interestingly, we found a larger 
median diameter of the largest liver cyst in PCLD patients than was found in studies 
on ADPKD patients.16’17 This is in line with another study comparing ADPKD and 
PCLD.17 It is unclear whether the age of onset is different from that o f ADPKD. 
Various series in ADPKD list a wide range (39, 46 and 56 years), while we found a 
median age of onset of 47 years.16’17’30
The autosomal dominant nature of PCLD should dictate an even male-female ratio. 
Similar to ADPKD, there is over-representation of females in our cohort (F:M = 
6:1).31 The most reasonable explanation is that PCLD runs a more severe course in 
female patients. Support comes from the finding that males have fewer symptoms, 
are older at time of diagnosis, and are more likely to be diagnosed at random 
abdominal screening. We included patients who had sought medical attention either 
for their symptoms or because they were diagnosed at random abdominal screening. 
The distinct hormonal profile is the most likely explanation for the female over­
representation. In ADPKD, pregnancies and postmenopausal estrogen treatment 
are associated with a selective increase of total liver volume.32’33 Moreover, estrogens 
induce cholangiocyte proliferation and growth.34’35 In our cohort, female patients 
who had been pregnant had larger cysts than the female patients who were never
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pregnant. In light of the clinical and experimental data, we have started to advise our 
female PCLD patients to discontinue systemic estrogen therapy.
We were not able to identify a single routine laboratory test that is highly discriminative 
for PCLD. We found elevated GGT and AP levels in 61% and 20% of patients, 
irrespective of severity of disease. The elevated AP and GGT levels probably reflect 
activation of cholangiocytes and is in line with ADPKD where both tests could be 
elevated as well.16’17’28’36’37
We found a mutation rate of 41%, which is higher than found in a previous genetic 
study.11 The difference is due to a higher prevalence of PRKCSH  mutations in our 
sample (33% versus 14%). Our patients were recruited largely because they sought 
treatment, while patients in the study of Davila et al. were recruited in the context of 
genetic research.11 The relevance of genetic testing is illustrated by the finding that 
the phenotypic expression of PCLD is more prominent in mutation carriers. These 
patients sought medical attention about 14 years earlier, and were more likely to have 
LT, than patients who were wildtype.
Treatment in polycystic livers aims to reduce liver volume and selection of a therapeutic 
option is mainly based on cyst location and size. As a corollary, not all (symptomatic) 
patients are eligible for treatment.38 Choice of treatment is dependent on insights 
which develop and change over the years. For example, laparoscopic fenestration 
only gained popularity after the early 90’s. There is a need for treatment in this group, 
as the median duration between diagnosis and treatment was only 2 years, and the 
majority was treated. We found that patients were treated with multiple therapeutic 
options and often more than once, which underlines the palliative nature of surgical 
treatment. The recent reports on the apparent beneficial effect o f somatostatin 
analogues, such as lanreotide for polycystic livers, offer hope that non-invasive 
treatments might be useful for this condition.39-41
An important feature of this study is the exhaustive characterization of the patients 
and long follow-up, which increases the understanding of this syndrome. Our patients 
were carefully followed and none of the patients refused medical follow-up. On the 
other hand, we cannot exclude the effect o f inclusion bias, because we included mainly 
symptomatic patients recruited from tertiary referral centers. Symptomatic patients 
are probably the most relevant proportion of PCLD patients, as asymptomatic 
patients appear not to have any significant disease burden. Our study is not biased 
towards patients carrying a PRKCSH  or SEC63 mutations, as all patients whom we 
genotyped visited one of the participating centers for medical reasons. We excluded 
ADPKD patients with polycystic livers, which limits application of our findings to 
the ADPKD population.
Finally, we performed a large cohort study in PCLD and found that females and 
PRKCSH  or SEC63 mutation carriers will have a more severe disease course. This 
suggests that patients with this risk profile should be carefully monitored.
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To study the extent to which aspiration-sclerotherapy reduces liver volume and 
whether this therapy results in relief of sym ptoms. Four patients, group I, with 
isolated large liver cysts, and eleven patients, group II, with polycystic livers, 
underwent aspiration-sclerotherapy. Average volume of aspirated cyst fluid 
was 1044 mL (range 225—2000 mL) in group I and 1326 mL (range 40—4200 
mL) in group II. M ean liver volume before the procedure was 2157 mL (range 
1706—2841 mL) in group I and 4086 mL (range 1553—7085 mL) in group II. 
T his decreased after the procedure to 1757 mL (range 1479—2187 mL) in group
I. In group II there was a statistically significant decrease to 3347 mL (range 
1249—6930 m L, p=0.008). Volume reduction was 17.1% (range -34.7% to -4.1%) 
and 19.2% (range -53.9% to +2.4%) in groups I and II, respectively. Clinical 
severity o f all symptoms decreased, except for involuntary weight loss and 
pain in group II. Conclusion: Aspiration-sclerotherapy is an means m ethod of 
achieving liver volume reduction and relief o f symptoms.
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Isolated liver cysts are very frequent—they have been detected in up to 18% of 
patients subjected to ultrasonography or CT scan.1-3 Liver cysts have been recognized 
increasingly as the routine use of imaging studies has become more widespread. The 
phenotype of a number of inherited syndromes dictates the presence of hepatic cysts. 
Radiographically, hepatic cysts in polycystic livers share the same architecture and are 
thought to arise from aberrant bile ducts.4
Polycystic liver disease (PCLD) is an autosomal inherited condition characterized by 
the presence of numerous cysts scattered throughout the liver. There are no, or only a 
few, cysts in the kidneys, which distinguishes it from autosomal dominant polycystic 
kidney disease (ADPKD), the most common cause of polycystic liver disease.4 
Although the hepatic phenotype of both syndromes is similar, the syndromes are 
separate entities, as is illustrated by the fact that both have different causative genes. 
PCLD is caused by mutations in the PRKCSH  gene and the SEC63 gene,5;6 whereas 
ADPKD is caused by mutations in the PKD-1 and the PKD-2 genes.7 PCLD probably 
results from ductal plate malformation, which is characterized by a disturbance 
in the physiological remodeling of the ductal plate.8 The multiple cysts arise from 
progressive dilatation of the abnormal ducts in biliary hamartomas,4 which are the 
result o f ductal plate malformation at the level of the small intrahepatic bile ducts. 
These small bile ducts have lost continuity with the remaining biliary tree, which 
explains the non-communicating nature of the cysts in PCLD.9 
Hepatic cysts are rarely symptomatic. Symptoms can arise due to growth of the cysts 
and are usually due to abdominal mass; examples include abdominal pain, early satiety, 
dyspnea, nausea, and vomiting and are mostly seen in females >50 years of age. Rarely, 
complications such as portal hypertension, cyst infection and cyst rupture occur.10 
The majority o f patients with multiple liver cysts are not in need of therapy. When 
patients become symptomatic, therapeutic options should be explored. The aim of 
therapy is to reduce cyst volume in order to achieve relief of symptoms and to prevent 
recurrence. Current management consists of aspiration-sclerotherapy of selected cysts 
or surgical approaches aimed at excising or obliterating cysts.11 Choice of treatment of 
PCLD is based on the number, size, and location of the cysts and on local expertise. 
Aspiration-sclerotherapy is a minor invasive option with low morbidity. The 
technique was first described in 198512 after the realization that aspiration alone led 
to 100% recurrence of cysts.13 Improvement of this procedure consists in additional 
sclerotherapy with ethanol or other irritants (antibiotics), after aspiration of the cyst 
contents, aimed at destroying the cyst lining epithelium.12’14-16
Though this method has slowly gained popularity, it is unknown if and to what extent 
it reduces liver volume, as this is arguably the main reason for the development of 
symptoms. Furthermore, it is unknown whether this treatment actually benefits
Intro d uctio n
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patients in terms of relief of symptoms.
To this end we designed this study with two aims in mind. First we aimed to evaluate 
the efficacy of aspiration-sclerotherapy in reduction of liver volume. Second we 
wanted to know whether symptoms experienced by patients with polycystic liver 
disease or large isolated hepatic cysts were improved by the procedure.
P a t ie n t s  a n d  Me t h o d s
Subjects
Between October 2004 and May 2007, fifteen symptomatic patients underwent 
ultrasonographically guided aspiration-sclerotherapy. Patients were subvided into 
two groups. Group I included four patients with isolated large liver cysts (two male, 
two female, mean age 51.3 years (SD 27.6, range 24—76 years)). Group II included 
eleven patients with PCLD, defined as >15 liver cysts (all female, mean age 55.0 years 
(SD 12.7, range 35—81 years)). Four patients of group II, carried a PRKCSH  gene 
mutation and none of them had a SEC63 gene mutation. The study was approved 
by the local medical ethical review committee (CMO regio Arnhem Nijmegen). All 
participants provided informed consent.
Procedure
All aspiration-sclerotherapy procedures to treat liver cysts were performed on an out­
patient base. Patients were put in a supine position. After locating a strategically located 
symptomatic cyst, the overlying skin was locally anaesthetized with lidocaine and a 
small incision was made. We performed ultrasound guided aspiration of the cyst with 
a 5 French straight catheter needle system or a 7 French pigtail needle system. The 
cyst was emptied via a three-way stopcock without allowing air to enter the collapsed 
cyst. After emptying the cyst, we proceeded to instill 96% ethanol (to a maximum 
of 27% of total aspirated volume). We usually inject and evacuate ethanol several 
times in order to ensure maximal ablation of the cystic wall. After 15 min (range 
10—20 min) the procedure was terminated by evacuation of all remaining ethanol and 
removal o f the catheter. I f  a patient experienced pain or complete aspiration of cyst 
fluid was not possible, in most instances because of the presence of cystic blood clots, 
no ethanol was instilled into the cyst and the session was abandoned.
Volumetry
Each patient undergoing aspiration-sclerotherapy was subjected to two multidetector 
computed tomography (CT) scans, before and after treatment, with a maximum 
interval of 18 months between the scans. Liver volumetry was performed on the 
multidetector CT-scan (Siemens Somatom Sensation 64) before the first session and,
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if there were more sessions, after the last session.
The digital CT images with 3 mm slice thickness were used for digital volumetry, 
using the Siemens Volume application. The liver was outlined manually, marking 
each 1—5 cm with a mouse click until the entire liver perimeter was outlined. This 
step was repeated each 9 mm through the complete length of the liver. The software 
intrapolated the intermediate slices and calculated the areas within the indicated 
circumference. Finally, the software calculated the liver volume by use of the 
equation V  = S x  A , where S  is the interval o f the serial slices (mm) and A  is the 
enclosed area (cm2). For comparison, four normal livers were evaluated. We measured 
four livers from four subjects that had had a CT scan for liver-unrelated reasons. 
There the average normal liver volume was 1550 mL (range 1230—1751 mL). The 
average difference between intraindividual observations was 35 mL (range 2—85 mL) 
measured in seven livers. That between interindividual observations 52 mL (range 
38—72 mL), measured in four livers.
Questionnaire
Patients were asked to complete a questionnaire with 12 abdomen-symptom-specific 
items. This symptom-based questionnaire was focused on the period before, during, 
and after treatment.17 It is a self-completed questionnaire, that has been validated, and 
can be used in a variety of clinical settings. This questionnaire included questions 
about the severity of the symptoms during the previous 4 weeks rated on a seven- 
point Likert scale (with 0 meaning “absent” and 6 “very severe”). A score of two 
or more was regarded as symptom presence. Furthermore, demographic variables, 
duration of symptoms, and overall severity (on a 100 mm visual analogue scale) were 
recorded. Questions that were not completed properly were excluded from further 
analysis.
Statistical analysis
Paired /-tests were performed to study differences between liver volume before and 
after the procedure and the severity of symptoms. Pearson’s correlation coefficient 
was used to compare the amount of aspirated fluid and liver volume reduction. A 
difference with a p-value of <0.05 was considered statistically significant.
R e s u lt s
Patients
Patient characteristics are shown in Table 3.1. No session was terminated prematurely 
because of pain. In total there were six aspiration-sclerotherapy sessions in group I 
and 23 in group II. A total o f 30 cysts were aspirated in group II. Two patients in
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group I and five in group II were subjected to a single session, while the remaining 
two and six had from two to four sessions. In group II, we aspirated a maximum 
of two cysts during each session. Figure 3.1 shows a typical result of the aspiration- 
sclerotherapy (patient 3). Here, the procedure led to a decrease in volume of 11.6%. 
The average volume of aspirated cyst fluid was 1044 ml (SD 729, range 225—2000 
ml) in group I and 1326 mL (SD 1194, range 40—4200 mL) in group II. The average 
amount of ethanol instilled in the cysts was 5.7% of aspirated volume (range 1.6­
13.3%) in group I and 8.3% (range 0.7—27%) in group II but never more than 50 mL. 
Mean clinical follow-up period after the last session was 21 months (range 8-30 
months) for group I and 14.5 months (range 3—27 months) for group II. Four patients, 
one of group I and three of group II, were referred for laparoscopic fenestration 
because of failure of symptoms to improve.
Figure 3.1 Aspiration-sclerotherapy
A CT scan  of th e  liver of a 74-years old m an  w ith  ADPKD an d  a large  iso la ted  cyst. B U ltraso u n d  of th e  sam e 
cyst b e fo re  a sp ira tio n . C CT scan  of th e  sa m e  reg io n  of th e  liver 4  m o n th s  la te r show s a reg ress io n  of th e  
iso la ted  cyst. D U ltraso u n d  g u id ed  a sp ira tio n  of th e  cyst.
Table 3.1 Patient characteristics
Sex Age* Diagnosis N o of sessions
Total aspirated 
cyst fluid (mL)
CT-volume 
before (mL)
CT-volume 
after (mL)
Livervolume 
change (%)
Group I
1 F 24 Single cysts 2 950 1801 1479 -17.9
2 M 31 Single cysts 2 1000 2281 2187 -4.1
3 M 74 Single cysts 1 225 1706 1508 -11.6
4 F 76 Single cysts 1 2000 2841 1855 -34.7
Group II
5# F 40 PCLD 4 1310 5489 4974 -9.4
6# F 58 PCLD 4 505 4897 4145 -15.4
7 F 65 PCLD 1 40 1553 1441 -7.2
8 F 81 PCLD 1 1400 3004 2424 -19.3
9# F 55 PCLD 1 1300 4195 2877 -31.4
10# F 35 PCLD 3 980 4275 4376 +2.4
11 F 61 PCLD 2 1100 2809 2164 -23.0
12 F 45 PCLD 1 500 6959 6930 -0.4
13 F 60 PCLD 2 4200 7085 4637 -34.6
14 F 57 PCLD 1 200 1974 1603 -18.8
15 F 48 PCLD 3 3050 2707 1249 -53.9
*Age reflects current age. "Indicates a PRKCSH mutation
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Volumetry
Average liver volume before the procedure, 2157 mL (range 1706—2841 mL) in group
I and 4086 mL (range 1553—7085 mL) in group II, was (statistically) much higher 
than that o f control livers, because of the large volumes of cystic livers. Average 
liver volume decreased to 1757 mL (range 1479—2187 mL) in group I and 3347 mL 
(range 1249 — 6930 mL) in group II after the procedures. This represents a reduction 
of volume of 17.1% (range —34.7% to -4.1%) in group I and 19.2% (range —53.9% to 
+2.4%) in group II. Liver volume reduction reached statistical significance in group
II with a mean liver volume decrease of 739 mL (95%CI 236—1241 mL,p=0.008). 
Liver volume decreased in all patients of group I and in nine patients in group II. One 
patient had only a slight decrease of liver volume and one patient had a slight increase. 
There was an excellent, significant, correlation between the volume removed by cyst 
aspiration and the final liver volume as assessed on follow-up CT scanning. In essence, 
larger volume on aspiration led to better results in terms of liver volume reduction (r 
= -0.87 p<0.0001) (Figure 3.2).
Figure 3.2 The relation betw een total aspirated cyst fluid and the liver volume
(r = -0 .86  p<0.0001)
Questionnaire
The response to the questionnaire was 100%. Table 3.2 shows the average degree of 
symptoms during treatment. There were two patients, both of group II, which did 
not experience any pain during treatment. Nausea and vomiting was noted by three
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patients, two of group I and one of group II.
Table 3.3 displays the average degree of symptoms before and after treatment. In 
both groups, the clinical severity of all symptoms decreased, except for involuntary 
weight loss and pain in group II. Specifically, the severity of postprandial fullness 
and abdominal distension decreased more than that of the other symptoms. Most 
patients o f both groups experienced a decrease of all listed symptoms, although some 
patients had an increase of one of the symptoms after treatment. Total pain increased 
in four patients (all in group II), was stable in three (one in group I and two in group 
II), while the remaining patients had a decrease in total pain. None of the differences 
reached the level of statistical significance.
Table 3.2 The average severity of symptoms during treatm ent
Symptom* Group I Group II
1. Pain
Insertion of catheter 2.7 2.0
During aspiration 2.8 1.5
During ethanol instillation 1.8 2.2
2. Nausea 0.9 0.5
3. Vomiting 0.7 0.3
'  S y m p to m s w e re  sco red  on  a ra n g e  o f  0 - 6  (0 = n o  sy m p to m ; 6 is very  severe).
D iscu ssio n
We found that aspiration-sclerotherapy in patients with liver cysts leads to a substantial 
reduction of liver volume and a corresponding decline of symptoms. It is minimally 
invasive and safe, can be done on an out-patient basis, and complications are rare. 
The therapy is effective for single liver cysts and for polycystic livers with large 
cysts, because it reduces liver volume and probably relieves symptoms. This will make 
aspiration-sclerotherapy part of the armamentarium to treat PCLD and large solitary 
liver cysts.
We evaluated four livers with a single cyst and eleven polycystic livers. The procedure 
as described in this study resulted in an average liver volume reduction of 17.1% 
and 19.2%, respectively. We elected not to treat patients with small liver cysts as it is 
unlikely this would not result in substantial reduction of liver volume.
An interesting difference between the two groups is the total liver volume. The 
volumes of livers with a single cyst, are smaller than polycystic livers. We found that 
the efficacy of the aspiration-sclerotherapy in terms of liver volume reduction was 
similar in both groups.
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Table 3.3 The average severity of symptoms before and after treatm ent
Symptom*
Group I Group II
Before After Before After
1. Abdominal pain:
General 1.7 1.0 0.9 0.6
Postprandial 1.7 0.7 1.0 0.4
Fasting 1.3 0.7 0.6 0.3
Unrelated to defecation 0.7 0 0.8 0.3
2. Epigastric pain:
General 1.2 0.3 1.7 1.S
During daytime 0.8 0.2 1.S 1.S
At night/asleep 1.0 0.3 1.4 1.4
3. Heartburn 0 0 1.6 1.0
4. Regurgitation 0 0 1.6 1.2
5. Nausea 0.7 0.3 1.1 1.0
6. Vomiting 0.7 0.3 0.2 0.2
7. Loss of appetite 1.2 0.S 1.S 1.2
8. Postprandial fullness 1.3 0.8 3.0 2.1
9. Shortness of breath 0.7 0.2 1.0 0.7
10. Abdominal distension 2.0 0.7 3.2 1.7
11. Involuntary weight loss 0.3 0 0.3 0.7
12. Pain 2.1 1.3 1.4 1.6
* S y m p to m s w ere  sco red  o n  a ra n g e  o f 0 -6  (0 = n o  sy m p to m , 6 = ve ry  severe)
We evaluated total liver volume rather than individual cysts, because symptoms 
in, especially, patients with polycystic livers arise from compression by severe 
hepatomegaly rather than the volume effect of a single strategically located cyst. As 
such, our study stands out because previously studies recorded the size of individual 
cysts rather than total liver volume. Liver volume measurement is used for the work­
up for liver transplant. In our hands the measurement was reproducible, and had 
limited intra- and interoperator variability. Although the procedure is currently not 
used in clinical practice it provides highly useful information and in the near future 
might be used to tailor the treatment options for PCLD.18-20
The efficacy of the aspiration-sclerotherapy exceeded our expectation and could be 
achieved in all except a single patient of group II. The liver volume of this patient 
increased with by 2%, despite an aspirated volume of 980 mL. At the moment it 
is uncertain why this single cyst was refractory to treatment. She was among two
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other patients of group II and one of group I who were referred for subsequent 
laparoscopic cyst fenestration.
We learned from our study that it is far more effective to evacuate large liver cysts 
(arbitrarily defined as > 8 cm) as these lead to a significant better volume reduction 
(Fig. 2). On the other hand, repeated (2—3) aspirations of these cysts are necessary to 
yield an acceptable volume reduction. In our hands the procedure does not lead to 
complete obliteration of the cyst but rather prevents it from expanding. For example, 
we were able to decrease large liver cysts (>20 cm) to less than 5 cm with adequate 
symptom control.
We used a questionnaire to score the severity of symptoms. Overall, there was an 
average decrease in the severity of symptoms. Abdominal distension and postprandial 
fullness were among the symptoms that were scored, in both groups, as most severe 
before treatment. These symptoms decreased after treatment. Moreover, most 
patients experience pain relief.
Apart from pain, we observed no complications such as infection of liver cysts or 
pleural fluid effusion.16 Pain could occur at any time during the procedure—when the 
catheter passes the liver capsule, upon fluid aspiration, and, finally, after injection of 
ethanol in the cyst. Patients describe the pain during ethanol instillation as a burning, 
but in most instances that abates quickly. Pain is seen in all studies as most common 
drawback of aspiration.12’14’16’21-26
Aspiration-sclerotherapy has several advantages over other approaches, because it is 
easy, can be performed on an out-patient basis and leads to few complications.14’27 
Our procedure has similarities to, and differences from, sclerotherapy described 
elsewhere.12’14’16’21-26’28 Similar to many other studies we used ethanol as sclerosing 
agent. It destroys the lining epithelium and leads to fibrotic obliteration which will 
impede production of cyst fluid.12 Other sclerosing agents such as minocycline, 
tetracycline or doxycycline destroy the lining epithelium by virtue of the highly acidic 
pH.14’15 These agents appeared to be similarly effective to ethanol.16 A risk of the use 
of a sclerosing agent such as ethanol is marked sclerosis of the bile ducts when it is 
injected into a cyst that communicates with the biliary tree.12 Therefore some authors 
argue that fluoroscopy should be used prior to instillation of ethanol.12’16’22’23’25’28’29 
We treated superficially located cysts that are not likely to communicate with the 
biliary tree, hence avoiding the need for verification by fluoroscopy. There is lack of 
objective data concerning optimum exposure time. Some authors instill ethanol for 
prolonged period but we chose a limited exposure time in order to limit the chances 
for complications.12’14’16’22-26 This is supported by another study that elected to leave a 
catheter for drainage after the sclerotherapy. The sclerotherapy was repeated if more 
than 10-15 mL cyst fluid was produced. In contrast with our findings, this study 
reports complications such as infection and pleural fluid effusion.16 Most likely, these 
complications could have been avoided if the catheter was removed immediately after
sclerotherapy. Several studies reported that the patients need to be turned over to 
various positions, in order to permit ethanol to come into contact with all surfaces of
the cyst cavity.12’14’15’22’23’25’26’28 This procedure was not part of our applied technique.
Aspiration-sclerotherapy is indicated in patients with symptoms that are associated 
with large liver cysts (>5 cm) and/or dominant cysts. Other patients, especially those 
with multiple small cysts scattered throughout the liver parenchyma, are candidates 
for other therapeutic options—open or laparoscopic liver cyst fenestration, partial 
liver resection, or liver transplantation. The choice between these modalities is made 
on the basis of the location of cysts , volume of the liver, and surgical experience. 
Open fenestration of cysts is more effective in terms of volume reduction, but the 
morbidity of laparoscopic fenestration is lower than that of the open procedure.30 
Patients with livers with a dominantly affected liver segment might be candidates for 
a partial liver resection, but the morbidity rate is higher than for the other procedures. 
Finally, liver transplantation is indicated if other therapies are no option or failed and 
if the patient is severely incapacitated by the large volume of the liver.10
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Patients with polycystic liver disease (PCLD) may develop sym ptoms due 
to increased liver volume. Laparoscopic fenestration is one o f the options 
to reduce liver volume and to relief symptoms. T his study was performed to 
evaluate the safety and efficacy o f laparoscopic liver cyst fenestration. Twelve 
patients (all female, m edian age 45 years, range 35-58) with symptomatic 
PCLD were included between A ugust 2005 and April 2007. Surgical data were 
recorded, liver volumes were measured on pre- and postoperative computed  
tomography (CT) scans, and patients com pleted a validated sym ptom-based  
questionnaire pre- and postoperatively. M edian preoperative liver volume was 
4854 ml (range 1606—8201) and decreased to 4153 m l postoperatively (range 
1556—8232) resulting in m edian liver volume reduction of 12.5% (range +9.5 
to -24.7%). M edian procedural tim e was 123.5 m in (range 50-318), and median  
hospitalization period was 3.5 days (range 1-8). Postoperative complications 
occurred in three patients including biliary leakage, obstruction of inferior 
vena cava and sepsis, all recovering with conservative managem ent. Patients 
reported decreased sym ptoms o f postprandial fullness and abdom inal 
distension. Conclusion: Laparoscopic fenestration in PCLD patients results in 
volume reduction o f 12.5% and decrease of symptoms.
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Simple hepatic cysts can be detected in up to 5% of patients subjected to conventional 
abdominal imaging techniques.1’2 Polycystic livers, characterized by a large number 
of liver cysts (>20) scattered throughout the liver parenchyma, are mostly seen in 
association with autosomal dominant polycystic kidney disease (ADPKD). Patients 
with ADPKD also have polycystic kidneys, a feature that is absent in patients with 
autosomal dominant polycystic liver disease (PCLD).3 The genetic basis o f both 
diseases is different; associated genes in PCLD are PRKCSH  and SEC63,4;5 while 
ADPKD is caused by PKD1 or PKD2 mutations.6
Symptoms in patients with a polycystic liver are mostly absent, but they may develop 
because of increasing cyst size. They mainly consist of abdominal pain, early satiety, 
dyspnea, nausea and vomiting.7 Complications directly related to the presence of cysts 
such as intracystic hemorrhage, infection, or rupture, are rare.8 
Treatment is indicated when symptoms are thought to be severe enough to warrant 
intervention.9 In general, therapy is aimed to reduce liver volume and to relieve 
symptoms. Several therapeutic options are presently available which include aspiration- 
sclerotherapy, cyst fenestration, partial liver resection and liver transplantation. The 
choice of treatment largely depends on number, size, and location of the liver cysts.8 
The technique of open fenestration of liver cysts was first described by Lin et al. in 
1968.10 This technique has been reported to be a safe and effective treatment for the 
management of symptomatic nonparasitic cysts o f the liver.11 In 1991, laparoscopic 
fenestration was introduced and appears to be equally effective.12;13 The cited 
advantages of laparoscopic fenestration as an alternative for the open procedure 
concern lower morbidity and mortality rates and a reduced hospital stay.8;14;15 In 
addition, it has been suggested that an open procedure may lead to the formation of 
adhesions, which may impede the possibility of a future liver transplantation.16 So 
far, laparoscopic fenestration has mainly been evaluated in patients with either single 
cysts or polycystic livers due to ADPKD, while data on PCLD are conspicuously 
scarce.
The purpose of our study is to evaluate the efficacy of laparoscopic cyst fenestration 
in terms of absolute liver volume reduction and symptom relief in PCLD patients.
Ma t e r ia l  a n d  Me t h o d s
Subjects
Twelve patients (all female, mean age 44.9 years, range 35-58 years) with symptomatic 
PCLD were treated between August 2005 and April 2007 for laparoscopic fenestration 
of liver cysts. Five patients had PRKCSH  gene mutations, two patients carried SEC63
Intro d uctio n
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mutations, whereas the remaining five patients were wild type for both genes. Six 
patients had been treated initially by aspiration-sclerotherapy, one patient had been 
subjected to (unsuccessful) laparoscopic marsupialization of one of her liver cysts, 
and another patient had a history of laparoscopic cholecystectomy for symptomatic 
cholecystolithiasis.
Multislice computed tomography (CT) scans were performed in all patients at a 
median interval o f 138 days before surgery (range 6-336 days). Based on this pre­
procedure CT-scan, patients were divided in groups according to the classification of 
polycystic livers as defined by Gigot et al.11: Type I included patients with a limited 
number (<10) of large cysts. Type II represented patients with diffuse involvement of 
liver parenchyma by multiple medium-sized cysts with remaining large areas of non- 
cystic liver parenchyma. Type III was a severe form of PCLD with massive, diffuse 
involvement of liver parenchyma by small-and medium-sized liver cysts and only a 
few areas of normal liver parenchyma between cysts.
Surgical procedure
Patients were positioned in a supine reversed Trendelenburg position. 
Pneumoperitoneum was established using an open introduction at the umbilicus, 
after which a 12-mm trocar was placed first. Based on inspection of the abdominal 
cavity and polycystic liver, three other trocars (5 and 12 mm) were placed at locations 
seeming most appropriate for fenestration.
Large and accessible cysts were punctured and aspirated with laparoscopic aspiration 
needle and subsequently deroofed by using ultrasonic dissection (Ultracision® 
harmonic scalpel, Ethicon Endo Surgery). The dissected wall and floor o f all cysts 
were inspected for bile leakage and bleeding; if necessary, hemostasis was performed. 
To facilitate future liver transplantation, omentoplasty was not performed. After 
fenestration of all accessible cysts, trocars were removed under direct vision, and the 
abdomen was desufflated before closure of the skin and fascia.
3D volumetry
Multislice CT-scan was repeated at a median postoperative period of 72.5 days 
(range 13-587 days). The effect o f the surgical procedure was evaluated by pre- and 
postoperative 3D total liver volume measurement of CT scan slices using Pinnacle3® 
version 8.0d (Philips, Eindhoven, The Netherlands). CT scans had a slice thickness 
of 3 mm, and the liver was outlined manually every 9 mm. The software interpolated 
the intermediate slices and calculated the areas within the indicated circumference, 
and finally, the total liver volume.
Q uestionnaire
Finally, all patients received a 12-abdomen-symptom-based questionnaire17. Patients
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completed the questionnaire 4 weeks before and 4 weeks after the procedure. 
Symptoms were scored from 0 (absence of complaints) to 6 (severe complaints).
Statistical analysis
Statistical analyses were performed using the paired t  tests and Pearson’s correlation 
coefficient, to study differences in severity of symptoms and compare symptoms with 
liver volume, respectively. A p-value of <0.05 was considered statistically significant.
R e s u lt s
Patient characteristics
Patient characteristics are outlined in Table 4.1. Four patients were classified as type
II polycystic liver disease and eight as type III. The median follow-up time was 352 
days (range 150-738 days).
Surgical procedure
Laparoscopic fenestration was technically successful in all twelve patients; there was 
no need for conversion to laparotomy. The median duration of the procedure was 
123.5 minutes (range 50-318 minutes). Minor intraoperative hemorrhage of the liver 
capsule occurred in four patients, which was easily controlled by surgical hemostasis. 
One patient had adhesions due to previous marsupialisation, but adhesiolysis 
facilitated a good view on the polycystic liver and did not hamper the procedure. The 
median hospitalization time was 3.5 days (range 1-8 days).
Three postoperative complications occurred (25%). One patient developed cold 
chills and fever indicating blood-borne sepsis. Blood culture revealed an enterobacter 
cloacae. She was admitted to the intensive care unit, received inotropic support, 
and was treated with intravenous cefuroxime, metrodinazole in combination with 
tobramycine and recovered within 2 days (hospitalization was 8 days).
For the second patient, the procedure went uneventful and appeared to be effective, 
until 8 weeks after fenestration when she presented with nausea, fatigue, and fever. 
She had an increased abdominal girth because of biliary ascites. A subsequent 
cholangiogram was compatible with biliary leakage (Figure 4.1). A nasobiliary drain 
was inserted and the leakage closed conservatively after 14 days. After readmission of 
41 days, she was discharged in a good clinical condition.
The last patient developed inferior vena cava obstruction with bilateral leg edema. 
She was treated with ultrasound guided aspiration of strategically located cysts and 
administration of diuretics, and she recovered, but after 3 months after surgery, there 
was still residual ascites despite diuretic therapy. She was hospitalized for a total of 
31 days.
Table 4.1 Patient characteristics
Age
(Years)
Gigot11
type
Intraoperative
complication
Postoperative
complication
Procedural 
duration (min)
1# 54 2 None None 91
2 58 2 None None 76
3# 39 3 None None 101
4* 40 3 None None 194
5# 35 3 Hemorrhage None 177
6 45 3 Hemorrhage Fever 195
T 37 3 Hemorrhage Bile leakage 251
8# 42 3 None None 117
9# 42 3 Hemorrhage None 318
10 47 2 None None 50
11 57 2 None None 82
12 43 3 None Vena cava infe­
rior syndrome
130
Age reflects age at operation t im e 1 PRKCSH-mutation *SEC63-mutation
Length of 
stay (days)
CT-volume 
before (mL)
CT-volume 
after (mL)
Liver volume 
ch a n g e(%)
1 2877 3151 +9.5
2 2150 1619 -24.7
2 4974 5089 +2.3
3 7143 6117 -14.4
3 4484 3655 -18.5
7 5302 4310 -18.7
4 6344 5010 -21.0
3 4735 3996 -15.6
5 7468 6675 -10.6
4 1718 1610 -6.3
8 1606 1556 -3.2
7 8201 8232 +0.4
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Figure 4.1 Biliary leakage as postoperative complication in laparoscopic fenestration
A C h o lan g io g ram  sh o w s a lea k ag e  o f  c o n tra s t (arrow ). B C h o lan g io g ram , m a d e  14 day s a f te r  A, sh o w s th a t 
th e  le a k ag e  is c lo sed .
Liver volumetry
We measured four livers from control patients who underwent CT scanning for liver 
unrelated purposes. The average volume of these livers was 1550 mL (range 1230-1751 
mL), which corresponds to other studies.18-20 The average variation in intra-individual 
observation was 1.2% (range 0.0-5.3%; seven livers), whereas the interindividual 
variation of the observations was 2.7% (range 2.5-2.8%; four livers).
The median liver volume before operation was 4854 mL (range 1606 — 8201 mL) and 
decreased to 4153 mL (range 1556 — 8232 mL) after the procedure. This comes down 
to a median reduction of liver volume of 12.5% (range +9.5 to -24.7%), although not 
statistically significant. Figure 4.2 shows a typical result of the procedure in a patient 
in whom we achieved a liver volume reduction of 15.6%.
Questionnaire
All patients completed the questionnaire pre- and postoperatively. The most 
frequent and severe symptoms recorded before surgery were abdominal distension, 
postprandial fullness, loss of appetite, and pain (Table 4.2). Before treatment, every 
patient reported severe abdominal distension. Eleven patients reported abdominal 
pain, with epigastric pain being most prominent. Postprandial fullness had been
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Figure 4.2 Sagital and transversal CT slices of patient 8
A a n d  B a re  p re o p e ra tiv e , C an d  D a re  p o s to p e ra tiv e
experienced by most patients (n=10) and was severe as well. On the whole, a trend 
to a decrease of all symptoms after laparoscopic fenestration was demonstrated, with 
a significant decrease of abdominal distension (p=0.01) and postprandial fullness 
(p=0.02). Three patients had complete remission of pain.
Pain scores decreased in patients with decreased liver volume and vice versa. 
Patients with liver volume increase reported an increase of pain. Figure 4.3 shows 
the correlation (r = -0.32, p=0.31) between liver volume change and decrease of 
symptoms. One patient (no. 4) reported more pain after laparoscopic fenestration. 
She was referred for liver transplantation.
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Table 4.2 The mean severity of symptoms before and after treatm ent
Symptom Before After
1. Abdominal pain:
In common 1.8 1.2
Postprandial 2.1 1.0
Fasting 1.6 0.9
Unrelated to defecation 1.2 0.6
2. Epigastric pain:
In common 2.2 1.1
During daytime 2.3 1.1
At night/asleep 1.8 0.8
3. Heartburn 1.7 0.8
4. Reguritation 1.6 0.7
5. Nausea 1.7 0.7
6. Vomiting 0.7 0.2
7. Loss of appetite 2.6 0.6
8. Postprandial fullness 3.6 1.1*
9. Shortness of breath 1.6 0.5
10. Abdominal distension 4.2 1.9*
11. Involuntary weight loss 1.2 0.3
12. Pain 2.2 1.7
All sy m p to m s w ere  sco red  on  a ra n g e  o f 0 -6  (0 = n o  sy m p to m , 6 = 'very severe). * in d ica te s  a sign ifican t de-
c rea se
D iscu ssio n
The goal of laparoscopic fenestration of liver cysts in PCLD is twofold: liver volume 
reduction by elimination of cysts and relief o f symptoms. In this series, a median liver 
volume reduction of 12.5% was achieved with a concomitant decrease of the severity 
of symptoms. This suggests that a procedure that results in liver volume reduction 
has the advantage of symptom relief (Figure 4.3).
The primary endpoint of our study was volume reduction, as assessed by liver 
volumetry on CT scanning. We found that this technique is reliable, precise, and 
appears to be helpful in estimating the therapeutic efficacy. In PCLD, symptoms are 
more likely related to the increased liver volume than to strategically located cysts. 
Hence, it is reasonable to measure total liver volume instead of single cyst size. The
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Figure 4.3 Correlation betw een total of pain decrease and liver volume change
Pain is sco red  o n  a sca le  o f  0-100. P a tien ts  w e re  g ro u p e d  acco rd in g  to  e ffec t o f th e ra p y  on  v o lu m e  an d  a b ­
d o m in a l pa in . A P a tien ts  w ith  in crease  o f pa in  an d  in c reased  liver vo lu m e . B P a tien ts  w ith  d e c re a s e  o f pain 
an d  in c reased  liver v o lu m e . C P a tie n ts  w ith  in c rease  o f pa in  an d  d e c re a s e d  liver vo lu m e . D P a tien ts  w ith 
d e c re a s e  o f  pa in  a n d  d e c re a s e d  liver v o lu m e . M ost p a tie n ts  h a d  a b e n e fit  in te rm s  o f  b o th  v o lu m e  re d u c tio n  
an d  d e c re a s e  o f  ab d o m in a l pa in  (panel D).
measured liver volumes before surgery match with the classification of Gigot et al.:11 
range of liver volumes in patients with type II was 1606-2877 mL and in patients with 
the most severe phenotype (III), range was 4484-8201 mL.
In 1997, Gigot et al. evaluated ten patients who had been treated by an aggressive 
attempt to reduce liver volume, mainly by open-liver cyst fenestration. Deep-sited 
cysts were also opened aided with intraoperative ultrasound. Here, the average liver 
volume decreased from 7761 mL to 4596 mL, a reduction of 43%. Both preoperative 
liver volume and volume reduction was larger than obtained in our trial. The main 
difference is that nine out of ten patients underwent open fenestration, and it appears 
that volume control can be better obtained with an open procedure under ultrasonic 
guidance. On the other hand, this approach is associated with a higher prevalence of 
intra- and postoperative complications such as intraoperative massive hemorrhage 
and a biliary tear, postoperative biliary leakage and ascites, and obstruction of the 
inferior vena cava. Intraoperative and postoperative complications are more common 
in patients with polycystic livers than in patients with single liver cysts. In our 
study, three patients (25%) had severe postoperative complications. These patients 
had a prolonged hospitalization or readmission with severe morbidity. The patient 
with the largest liver volume (8.2 L) developed inferior vena cava obstruction. We
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speculate that as a result of the fenestration, the liver got dislodged with subsequent 
compression of the inferior vena cava. Ultimately, all three patients improved on 
conservative management.
Our series had a median operation time of 123.5 min, which is comparable to 
operating times from other series.11’14’21-30 Overall mean length of stay from our study 
(3.5 days) was shorter than data from the literature (1-11 days).11’14’21-30 
One possible limitation is that the follow-up of patients in our series is not particularly 
long, which makes the recurrence rate difficult to judge. There was recurrence of 
symptoms in patient no. 1 (follow-up 18 months) which matched increased liver 
volume on CT. Although the natural history of PCLD dictates disease progression, 
its actual rate is not known. In our study, the time range between preoperative and 
postoperative CT scan among individual patients was considerable, which may have 
led to underestimation of the effect of the procedure. It is difficult to compare our 
recurrence rate to literature, in view of lack of an explicit definition of recurrence. 
Some authors defined recurrence as recurrence of cysts on imaging techniques, others 
as recurrence of symptoms, while some included both symptomatic and radiological 
recurrence. On the other hand, the majority of studies report recurrences-what 
makes laparoscopic fenestration not a definitive therapy for patients with polycystic 
livers.11;14;21-30
In view of the progressive nature of polycystic liver disease, we regard laparoscopic 
fenestration as a palliative measure. This emphasizes the need for a strict selection 
of patients to improve the efficacy of the operation and to decrease morbidity and 
mortality rate of this technique. There is a trade-off between benefit and the morbidity 
associated with the procedure. Our data do not allow a firm statement which patients 
will benefit most, but we observed a major complication in a patient with a very large 
liver of 8.2 L in accordance with earlier reports in the literature. Ongoing clinical 
evaluation of laparoscopic fenestration is needed in order to allow tailored patient 
selection. In our view several factors affect the decision to perform laparoscopic 
fenestration: (1) liver volume, (2) diameter of individual cysts, (3) location of cysts, 
(4) complications by strategically localized cysts, (5) availability of experienced 
laparoscopists, (6) possible candidacy for potential liver transplantation. Although 
not formally supported by our study, patients with fairly large (>4 cm) well accessible 
located cysts who will not be an imminent candidate for liver transplantation seem 
fine candidates for the procedure. Cysts located in segments VI, VII, and VIII o f the 
liver and/or located deep inside the hepatic parenchyma are difficult to reach with 
laparoscopic fenestration.14 Dominant large liver cysts, are better suited for aspiration- 
sclerotherapy because this is less invasive than laparoscopy.31 Other therapeutic 
options are partial liver resection, especially if cysts are restricted to a limited number 
of liver segments, but is more invasive and potentially affects the possibilities for 
future liver transplantation given the risk of adhesions.8’11
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In conclusion, laparoscopic fenestration is a therapeutic option in the symptomatic 
treatment of PCLD. The procedure induces liver volume reduction with subsequent 
symptom relief.
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With great interest we have read the article by Schnelldorfer et al.1 They describe a 
single center cohort of polycystic liver patients, who underwent partial hepatectomy 
with cyst fenestration of the liver remnant (n=124), cyst fenestration alone (n=10), 
or liver transplantation (n=7). As such this is an update from their earlier series 
on 31 patients resected between 1985-1993.2 The authors point out that surgery in 
polycystic liver is associated with significant morbidity, but conclude that the degree 
of symptomatic relief and consequential improvement in performance status and 
overall health, warrants its use. Consequently, they advocate hepatic resection as a 
valid treatment option in selected polycystic liver patients. We are grateful for the 
efforts o f the authors to bring their collective experience to the table, but for several 
reasons we would like to share our concern about their conclusions.
The authors rightly point out that their series is the largest reported so far in 
medical literature. However, this is an immediate area for concern as it limits the 
generalization of the concept. We performed a thorough search in the literature to 
reveal all reported cases o f patients with polycystic liver who underwent resection. 
We used the PubMed interface (http://www.ncbi.nlm.nih.gov/entrez) and our search 
strategy was performed with the following terms: polycystic liver; resection, for the 
period 1981-2009. Articles written in English were considered for inclusion. The 
references o f the traced articles were scrutinized for additional papers. The search 
resulted in 26 publications reporting on 116 patients and only 10 series are larger than
4 patients (Figure 5.1). We found only 3 larger series on hepatic resection published 
in this century.3-5 These findings illustrate an important drawback of this technique 
nowadays: most centers do not have caseload to build expertise. Indeed, experience 
is one of the most critical factors that predict success. It took these authors of a 
renowned tertiary referral center 22 years to perform 124 procedures, which comes 
down to 5.6 patients per year. So even at a high volume center this procedure is 
performed infrequently.
One of the reasons that physicians are reluctant to advise this procedure may be that 
complication risk is high. Indeed, the authors cite a procedure related morbidity of 
63%, while ~50% of these complications are major (Clavien grade: III to V). This is 
probably related to the fact that the normal anatomy of polycystic livers is extremely 
distorted, as the liver is not only larger, but it is rigid with limited mobility and there is 
difficult access to vascular supply.1 These elements count towards the long operation 
times (average 324 min). The authors accept the high complication rates, because once 
the complications are resolved, the clinical performance status improves. We have 
little hope that the frequency of complications for hepatic resection will diminish 
significantly in the future. This is supported by the finding that the average hospital 
stay in their first series (1985-1993) was 11 days, while the current series cites an
To t h e  E d it o r :
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Figure 5.1 Publications on liver resection for polycystic liver
average of 13 days. Thus, despite clear improvements in supportive clinical care over 
the last years, hospital stay for this indication has increased.
An important drawback for hepatic resection is the high rate of adhesions. This 
is an unfavourable factor for future liver transplantation as explantation of the 
adhered liver becomes difficult. The authors favour partial hepatectomy above liver 
transplantation. Indeed, organ allocation is difficult in patients with a polycystic liver 
and preserved liver function. Despite these considerations, the authors report on 7 
patients who underwent orthotopic liver transplantation and cite a 5-year patient 
survival of 60%. This compares unfavourably with other series. For example, we 
found that in a large cohort of 58 patients with isolated polycystic liver disease the 
5-year patient survival was 92% and in the cohort with 121 patients with polycystic 
kidney and liver disease this survival rate was 89%.6 The collective experience on 218 
patients from the European Liver Transplant Registry indicated a 5-year survival of 
80%.7
On balance we think the morbidity and mortality rate is too high for this group 
who had ECOG PS 0 or 1. We think that other options with lower complication 
rates, such as laparoscopic fenestration and aspiration-sclerotherapy and even liver 
transplantation, should be fully explored before hepatic resection is considered.8-10 
We believe that future efforts should be directed towards medical management of 
polycystic livers. Indeed, treatment with somatostatin analogues appear to be feasible 
in these patients.11;12 and the first report of randomized clinical trial will be published 
soon.13
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Patients with end-stage isolated polycystic liver disease (PCLD ) suffer from 
incapacitating symptoms due to huge liver volumes. Liver transplantation 
(LT) is the only curative option. We aimed to assess its feasibility in PCLD  
and compared with that in autosomal dominant polycystic kidney disease 
(ADPKD). We used European Liver Transplant Registry (ELTR ) database 
to extract demographics and outcome of 58 PCLD  patients. Patient and 
graft survival rates were compared with those of 121 ADPKD patients who 
underwent LT. We used Kaplan-Meier survival analysis for survival rates and 
used the Log-Rank test to compare the survival rates between the two cohorts. 
The most prominent symptom in the PCLD  cohort was severe abdominal pain 
(75%) and complication portal hypertension (35%). Explantation of polycystic 
liver was extremely difficult 38%, probably due to presence of adhesions 
resulting from prior therapy (17%). Karnofsky score following LT was 90%. 
The 1- and 5-year graft (94.3% and 87.5%) and patient (94.8% and 92.3%) 
survival rates for PCLD  patients did not differ from that in ADPKD. Survival 
after LT for polycystic liver is similar for PCLD  and ADPKD.
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Polycystic livers are characterized by the presence of numerous cysts scattered 
throughout the liver parenchyma.1 Most cases have polycystic kidneys as well and 
suffer from autosomal dominant polycystic kidney disease (ADPKD). A minority of 
patients suffer from inherited, isolated polycystic liver disease, known as autosomal 
dominant polycystic liver disease (PCLD).1 Though polycystic livers are a feature of 
both ADPKD and PCLD, the genetic background of these two disorders is different 
because a distinct set o f genes have been implicated.2
Symptoms are dependent on the volume of the polycystic liver, and develop due to mass 
effect of large liver, including abdominal pain, abdominal distension, postprandial 
fullness, and dyspnea.1;2 The polycystic liver retains its normal physiological features 
and even in advanced stage synthesis and excretion is preserved. The most severe 
complications, such as portal hypertension and inferior caval vein syndrome, occur 
rarely, but are notoriously difficult to treat.3
In view of the rarity of PCLD, its therapeutic algorithm is under debate.2 Aspiration- 
sclerotherapy, open or laparoscopic fenestration and partial liver resection are 
current therapeutic options.4 The main limitation of these techniques is that they 
are only appropriate in highly selected patients, and offer only temporary relief of 
symptoms.2;3;5;6 More recently, liver transplantation (LT) has surfaced as a last resort 
alternative in patients with massive polycystic livers. In this respect there are several 
important issues that need to be addressed. It is unknown whether the underlying 
cause o f polycystic liver (PCLD or ADPKD) affects outcome. ADPKD is associated 
with important cardiovascular manifestations such as hypertension, left ventricular 
hypertrophy and cardiac valve abnormalities. These manifestations, a major source 
of morbidity and mortality in ADPKD, are absent in PCLD.7 Further, the experience 
with LT for polycystic liver is in most institutes limited to a handful cases precluding 
an adequate overview of the procedure related morbidity and mortality.8-19 In addition, 
long-term follow-up data on patient and graft survival are lacking. The primary 
hypothesis of this study is that survival after LT for polycystic liver disease is better 
in PCLD than for ADPKD.
To evaluate the validity of this hypothesis, we assessed the outcome of LT in two 
cohorts (PCLD and ADPKD) from the European Liver Transplantation Registry 
(ELTR). This study demonstrates that LT for polycystic liver leads to excellent patient 
and graft survival and shows that the outcomes are comparable for ADPKD and 
PCLD.
I n tr o d u c tio n
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The ELTR database contains data on a total of 534 patients who underwent LT with 
main or associated diagnosis ‘polycystic liver’, between November 1985 and June 
2007. Demographics and outcome parameters were extracted from the database. 
In order to select those patients with PCLD, we initially excluded 193 patients on 
the basis o f the finding that polycystic disease was not restricted to the liver (i.e. 
patients underwent combined liver-kidney transplantation (L-KT). We also excluded 
42 patients who were transplanted but in whom polycystic liver was not the main 
indication for the procedure.
We persued to collect additional data for the remaining299 patients using a standardized 
questionnaire, which was sent to 75 European LT centers. The questionnaire included 
items that focused on diagnosis, e.g. PCLD or ADPKD; family history; data on the 
pretransplant period, including symptoms, complications, laboratory results and 
prior therapies; data on the peritransplant period including indication of LT, with 
the following three options: mechanical difficulties (defined as expansion of the liver 
volume to such an extent that it compromised function or location of adjacent organs), 
invalidation (defined as impaired in daily life and quality of life) and complications 
resulting directly from the polycystic liver, such as portal hypertension; further 
peritransplant data included surgical aspects of transplant procedure and weight of 
the excised liver; data about the postoperative period, including length of admission, 
postoperative complications and quality o f life after LT using the Karnofsky score.
A total o f 49 centers responded and returned questionnaires on 191 patients. We 
could further exclude 12 patients who had another diagnosis than ADPKD or PCLD, 
such as cystic fibrosis (n=2), hepatic hemangioma (n=1), hepatic cellular carcinoma 
(n=1), Caroli’s disease (n=2) and hereditary amyloidosis (n=1), polyadenomatosis 
(n=1) or were unknown in the center (n=4). The final data set contains 121 patients 
were diagnosed with ADPKD and our final data set contains 58 patients with PCLD, 
who were transplanted in 25 LT centers (Figure 6.1).
Statistical analysis
In our PCLD cohort, laboratory results were calculated to the upper limit o f normal 
(ULN) of each individual LT center. Descriptive statistics are provided as total 
number and percentage for categorical variables. Continuous variables are given 
as median with interquartile range (IQR) distribution. Kaplan-Meier analysis was 
used to estimate the posttransplant patient and graft survival rate in the PCLD and 
ADPKD cohorts. Log-rank test was used to compare the survival rate between these 
groups. All statistical analyses were performed with SPSS version 16.0 (SPSS Inc., 
Chicago, IL, USA). Statistically significance was considered with p-value <0.05.
P a t ie n t s  a n d  m eth o d s
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Figure 6.1 Patient selection
R esults
Demographics of the PCLD  cohort
Fifty eight PCLD patients (10 males, 48 females) were transplanted in 25 LT centers 
in 11 European countries. Table 6.1 depicts the demographic characteristics of the 
cohort. Median age at time of diagnosis was 39.8 years (IQR 35—47) and 52.3 years 
(IQR 44—56) at time of LT. Severe abdominal pain (38 patients; 75%), abdominal 
distension (39 patients; 75%), and dyspnea (27patients; 53%) were among the most 
common symptoms. There were 28 (55%) patients who had developed one or more 
complications from their liver cysts, among which portal hypertension was most 
common (19 (35%) patients). All reported laboratory results were within the normal 
range, except for alkaline phosphatase (AP) and y glutamyl transferase (GGT) (AP 
median 1.50 (IQR 1.00—2.45) and GGT median 3.08 (IQR 1.26—6.07)). Thirty four 
(59%) patients underwent prior therapy, such as aspiration with (14 patients) or without 
(15 patients) injection of a sclerosant, laparotomic (13 patients) or laparoscopic (7 
patients) fenestration or partial liver resection (7 patients).
Peritransplant period
Primary reasons for LT were mechanical difficulties in 35 patients (60%), incapacitation 
in 14 patients (24%), and pain in 11 patients (19%). The transplant team decided to 
perform LT in 7 patients (12%) because of the severity o f complications such as
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portal hypertension and cyst infection. Median operation time was 6.6 hours (IQR 
4.8—8.3). Median blood loss was 1520 mL (IQR 500—4500). Median weight o f the 
explanted liver was 5890 grams (IQR 3019—9858). Explantation of the polycystic liver 
was considered extremely difficult in 22/58 patients (38%) because of adhesions due 
to prior therapy (n=10; 17%), grossly enlarged liver (n=7; 12%), and miscellaneous 
causes (n=3; 5%). Inability to explantation led to premature termination of LT 
procedure in one patient.
Post-operative complications were more frequent than in intra-operative complications 
(46% versus 17%) (Table 6.2). Median stay at the intensive care unit (ICU) was 5 days 
(IQR 2—9) while total admission length was 23 days (IQR 13—35).
Table 6.1 Baseline characteristics of patients transplanted for PCLD
Total (n=58)
Age at diagnosis* (years) 39.8 (34.6-46.9)
Age at LT* (years) 52.3 (43.6-56.4)
Sex, M /F 10/48
Symptoms
Abdominal pain* 38/51 (75)
Abdominal distension* 39/52 (75)
Dyspnea* 27/51 (53)
Postprandial fullness* 21/45 (47)
Weight loss* 22/51 (43)
Anorexia* 13/48 (27)
Nausea* 8/47 (17)
Vomiting* 4/47 (9)
Any complication* 28/51 (55)
Cyst infection* 9/55 (16)
Cyst hemorrhage* 4/52 (8)
Cyst rupture* 3/53 (6)
Portal hypertension* 19/55 (35)
Ascites* 18/54 (33)
Varices* 4/53 (8)
IVC syndrome* 3/54 (6)
*D ata are  m ed ian  (IQR); * n/N (%) D en om in ators d e p e n d  on  th e  n u m ber o f p rov ided  an sw ers for a specific  
q u e stio n  in th e  q u estio n n aire . D ata for creatin ine, a sp a rta te  tran sfera se  (AST), a lan in e  tran sfera se  (AST), a l­
kaline p h o sp h a ta se  (AP), y g lum atyl tran sfera se  (GGT), bilirubine, album in  and  INR and  w ere  norm alized  and 
ca lcu lated  a s  tim es o f th e  u p p e r limit o f  norm al (ULN); LT, liver tran sp lan tation ; IVC, inferior ven a  cava
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Table 6.1 Continued Baseline characteristics of patients transplanted for PCLD
Total (n=58)
Laboratory results
Creatinine*, times ULN 1.00 (1.00-1.00)
AST*, times ULN 1.00 (1.00-1.19)
ALT*, times ULN 1.00 (1.00-1.17)
Alkalic phophatase*, times ULN 1.50 (1.00-2.45)
Y glutamyl transferase*, times ULN 3.08 (1.26-6.07)
Bilirubin*, times ULN 1.00 (1.00-1.07)
Albumin*, times LLN 1.00 (1.00-1.00)
INR* 1.10 (1.00-1.18)
Prior therapy* 33/57 (58)
Aspiration* 14/33 (42)
Aspiration-sclerotherapy* 12/33 (36)
Open fenestration* 12/33 (36)
Laparoscopic fenestration* 7/33 (21)
Partial liver resection* 7/33 (21)
'D ata  are  m edian  (IQR); * n/N (%) D en om in ators d e p e n d  on  th e  n u m ber o f  p rov ided  an sw e rs for a specific  
q u e stio n  in th e  q u estion n aire . D ata for creatin ine, a sp a rta te  tran sfera se  (AST), a lan in e  tran sfe ra se  (AST), al­
kaline p h o sp h a ta se  (AP), y g lum atyl tran sfera se  (GGT), b ilirubine, a lbum in  and  INR and  w ere  norm alized  and 
ca lcu lated  a s  tim es o f  th e  u p p e r  limit o f  norm al (ULN); LT, liver tran sp lan tation ; IVC, inferior vena cava
Table 6.2 Operative complications
Intra-operative
complications
n /N  (%)
Post-operative
complications
n /N  (%)
Vascular 6/58 (10) Rejection 8/56 (14)
Venous tear 2/58 (3) Vascular 8/56 (14)
Revascularisation problem 2/58 (3) Infection 6/56 (11)
Bleeding 2/58 (3) Non-function graft 1/56 (2)
Hepatic vein thrombosis 1/58 (2) Death 1/556 (2)
Death 1/58 (2) Other 14/56 (25)
Other 3/58 (5)
Total 10/58 (17) Total 26/56 (46)
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Survival after LT in PCLD
Two patients (3.6%) died during admission, one intra-operatively and one after seven 
days because o f sepsis. Median survival time in this study was 6.0 years (IQR 2.5­
11.8). The 1-year and 5-years patient survival are 94.8% and 92.3%. Two patients 
had to be retransplantated: one patient after 7 days because of primary dysfunction 
and the second patient after 2.2 years because of artery thrombosis and anastomotic 
biliary stenosis. Graft survival was 94.3% at 1 year and 87.5% at 5 years.
Four patients died at follow-up between 4.7 and 12.4 years after LT. One patient 
died 5.9 years posttransplantation because o f metastasized malignancy with primary 
tumor, a second patient died after 8.7 years with chronic graft rejection and long-term 
assisted ventilation. For the remaining two patients reason of death is unknown (died 
4.7 years and 12.4 years posttransplantation). Patient characteristics o f the deceased 
patients were comparable with the other patients, except for age at diagnosis and age 
at LT: 48.0 years (IQR 36.4—63.5) versus 39.2 years (IQR 34.0—45.9) and 57.4 years 
(IQR 51.6—60.5) versus 51.9 years (IQR 42.7—55.2), respectively.
The median Karnofsky score for patients who are still alive was 90%, which indicates 
that they are capable o f normal activity, with only few symptoms or signs of disease.
Survival after LT in ADPKD
Because we wanted to contrast patient survival of PCLD with that of ADPKD 
patients, we studied the additional cohort consisting of 121 liver transplanted 
ADPKD patients (17 males, 104 females; median age at LT 47years (IQR 40—52)). 
The median survival time was 3.4 years (IQR 0.6—7.1). The 1-year patient survival was 
92.0% and 5-year was 88.9%. The graft survival was 86.8% for 1 year and 82.6% for
5 years. Both patient and graft survival were equal for ADPKD and PCLD (Table 
6.3; Figure 6.2). Table 6.3 shows that patient survival after LT is equal for ADPKD 
an PCLD.
Table 6.3 Baseline characteristics and survival rates in the different groups
PCLD ADPKD
N 58 121
Female (%) 48 (83) 104 (86)
Age at LTx (years)* 52 (44-56) 47 (40-52)
Survival time (years)* 6.0 (2.5-11.8) 3.4 (0.6-7.1)
1-year patient survival (%) 94.8 92.0
5-year patient survival (%) 92.3 88.9
1-year graft survival (%) 94.3 86.8
5-year graft survival (%) 87.5 82.6
*D ata are  m ed ian  (IQR)
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Figure 6.2 Patient survival o f PCLD and ADPKD
In o n e  PCLD p atien t th e  tran sp lan tation  p ro ced u re  w as prem atu rely  te rm in ated . This p atien t is in clud ed  in 
th e  survival an aly sis a s  in tra-operatively  d e a d .
D iscu ssio n
This study evaluated LT in a large cohort of PCLD patients and showed an excellent 
1- and 5 year patient and graft survival (Table 6.3; Figure 6.2). Contrary to our 
expectations, the LT results are independent of the underlying disorder. LT results 
were similar in the PCLD and ADPKD cohorts. Indeed, the demographic features 
and peri-operative data from our study are in line with smaller LT series which mainly 
included ADPKD patients.8-21 Comparison of the LT results for PCLD compared to 
other indications sheds a favorable light. The collective survival data from the ELTR 
database, which comprises patients with a wide spectrum of liver diseases, clearly 
shows a better survival for PCLD, because the 5-year patient survival in PCLD is 
92% compared to 75% for all indications.22 Only a few studies report on patient and 
graft survival rates o f LT in patients with polycystic liver due to PCLD or ADPKD. 
One study in 36 patients, including 15 patients who underwent L-KT, found a 1-year 
patient survival rate o f 86%.21 In 2003 the ELTR database, which brings together the 
collective experience on 218 patients with both PCLD and ADPKD, including L-KT, 
reported 85% (1 year) and 80% (5 year) patient survival rates.23 
The most important obstacle during LT was the explantation of the polycystic liver 
in most part because o f adhesions from previous surgical procedures. Extensive
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adhesions might preclude successful execution of the procedure. Other authors report 
on similar issues.9;12;14 These experiences suggest that reluctance to subject polycystic 
liver patients who are potential LT candidates to other invasive liver volume reducing 
procedures is warranted.
The place of LT in treatment of PCLD is subject of ethical discussion, as the polycystic 
liver has a normal synthesis capacity and the disorder appears to be not associated 
with excess mortality. In times o f shortage of donor organs, is it justified to allocate 
a liver to a patient with PCLD? Do we want to give otherwise healthy patients life­
long immunosuppression while also exposing them to a higher risk of infections and 
malignancies? In an effort to address this issue, Kirchner et al. evaluated the outcome 
and quality of life in patients with polycystic livers after LT or combined L-KT.21 
Transplantation improved actual health status and symptoms and quality of life to a 
level comparable to that o f an age-matched general population which accords with 
our data. The improvement of quality of life after transplantation, support the choice 
o f LT as a therapeutic option in PCLD.
There are several limitations inherent to this study. One potential caveat is that the 
observational nature led to ascertainment bias. For example, it is possible that only 
highly selected cases were included. We cannot exclude that on the basis of this study, 
but the fact that patients were selected by 48 centers from 11 countries limits the 
possibility of systematic selection. Another limitation is that observation period 
was from 1985-2007. We now know that results from LT in terms of patient and 
graft survival have improved over time.22 The relatively good survival data from 
our cohort study suggest that the room for improvement is limited. Thirdly, we 
pooled results from multiple LT centers who have different surgical and therapeutic 
protocols, including immunosuppressive therapy. On the other hand, this suggests 
that the success of LT in PCLD is independent from treatment center which helps in 
interpreting the general applicability o f this procedure.
Since December 2006, the allocation of liver grafts in Europe is based on the Model 
for End-stage Liver Disease (MELD). As patients with polycystic livers do not have 
an impaired liver synthesis, the M ELD score will be low in PCLD patients. Indeed, 
the calculated median M ELD score in our PCLD cohort was 6 (data not shown). 
This suggests that the M ELD score does not accurately select those PCLD patients 
that benefit most from LT. There has been an attempt to design criteria for patients 
with a polycystic liver, which should be met in order to be listed (Table 6.4).24 Patients 
who meet these criteria, should be granted a M ELD score exception: patients without 
and with renal insufficiency (glomerular filtration rate or creatinine clearance <30 
mL/min) may receive a M ELD score o f 15 and 20, respectively. The score may be 
increased by an additional 3 points every 3 months upon reapplication. The midarm 
circumference measured in the non-dominant arm has been added as a criterion for 
M ELD score exception. In our view, this is a rather artificial proxy parameter for
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malnourishment. We have analysed a set o f 13 female patients with severe PCLD 
(median liver volume of 4648 mL) and found that the median midarm circumference 
of the non-dominant arm was 27 cm, higher than the maximum threshold of 23.1 cm 
that is required for M ELD exception (unpublished data). This suggests the utility of 
this parameter is rather limited.11;12;14;25;26
Table 6.4 Criteria for listing patients with a polycystic liver for liver transplantation :
Massive polycystic liver and complication o f polycystic liver which is likely to resolve 
after LT
Not a candidate for, or failed to respond to, nontransplant interventions for relief of 
symptoms
Clinically significant manifestations o f liver disease that can be attributed to massive 
polycystic liver: cachexia, ascites, portal hypertension, hepatic venous outflow obstruc­
tion, biliary obstruction, cholestasis, recurrent cyst infection
Severe malnutrition
Serum albumin <2.2 mg/dL
Lean body mass, reflected by decreased midarm circumference, measured in the 
nondominant arm midway between acromion and the olecranon process: <23.1 cm in 
female patients and <23.8 cm in male patients
In our view, the only objective measurement of disease in polycystic livers is the liver 
volume, and a minimum threshold (for example 5000 mL) would clarify the issue. In 
addition, the hepatic anatomy, severity of symptoms, and general health status should 
be considered in the selection of LT.27 All in all, we think that liver transplantation 
for a polycystic liver should be provided in carefully selected cases.
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Polycystic livers occur in the setting of two inherited conditions: (1) autosomal 
dominant polycystic kidney disease (ADPKD), also characterised by progressive 
development o f renal cysts resulting in loss o f renal function, and (2) polycystic liver 
disease (PCLD), with a polycystic liver as the sole manifestation. Symptoms, such as 
abdominal distension, result from hepatomegaly. Ascites is a rare complication and 
might be due to portal hypertension or caused by a ruptured cyst.
Treatment strategies for polycystic livers are aimed at reducing liver volume. So far, 
only surgical options are available, but these are associated by considerable morbidity 
and mortality.1 Alternatively , ascites in the setting of polycystic livers might respond 
to endovascular stent placement in the narrowed caval vein,2 but medical options are 
conspicuously lacking so far. We wish to report two cases with severe polycystic liver 
disease that were successfully treated with somatostatin analogues.
A 53-year-old woman, with ADPKD complicated by a polycystic liver presented 
with abdominal pain and increased abdominal distension. Her renal function was 
normal. On physical examination she had hepatomegaly. An abdominal CT scan 
demonstrated ascites, a polycystic liver and a ruptured liver cyst. She was treated 
with diuretics (spironolacton 25-50 mg/day and furosemide 40 mg/day), but ascites 
progressed with concomitant increase of the abdominal distension and onset of 
orthopnea. Drainage of ascites (7 liters, serum ascites albumin gradient of 23.8 g/L) 
yielded only temporal relief. As no other therapeutic options were available, octreotide 
(50 |ag/h intravenously) was started 9 months after the onset of ascites. Within days, 
the patient improved and we switched to octreotide 100 ^g subcutaneously (three 
times a day). After 1 month, her abdominal distension had disappeared and diuretics 
could be stopped. Three months after start of octreotide treatment, the patient was 
free o f abdominal pain. 3D-volumetry of the polycystic liver was performed using 
Pinnacle3 (version 8.0d, Philips, Eindhoven, The Netherlands) according to previously 
published methods.3 A CT scan 112 days after the start of octreotide demonstrated a 
decrease of liver volume from 4609 mL to 2843 mL (38.3%) and kidney volume (left, 
from 246 mL to 240 mL (2.4%); right, from 554 mL to 455 mL (17.9%)) (Figure 7.1). 
The second patient, a 43-year-old woman with PCLD, developed ascites and oedema 
due to inferior caval vein syndrome, 11 days after laparoscopic fenestration of liver 
cysts. Her weight had increased from 79 to 94 kg. In order to relieve the caval 
pressure, three cysts were aspirated and 14.5 litres ascites was drained, without much 
benefit. One month after surgery, we started her on octreotide (100 ^g three times 
a day subcutaneously) and 12 days later we switched her to lanreotide (120 mg once 
a month subcutaneously). 3D-volumetry of the polycystic liver 230 days after start 
of treatment demonstrated a volume decrease o f 14.9% (from 8232 mL to 7004 mL). 
Renal function remained unchanged over this time period (creatinine previously 42 
^mol/L, and after 46 umol/L).
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Figure 7.1 Somatostatin analogues decrease cyst volume in polycystic liver diseases
CT scan  prior to  (A) and  a fte r  trea tm en t (B). V olum etry sh ow ed  a d e c re a se  o f  liver v o lu m e from  460 9 m L  to 
2843 mL.
Both patients developed intractable ascites secondary to polycystic liver disease. While 
liver transplantation was considered, we decided to start somatostatin analogues first. 
In both patients, this resulted in a dramatic clinical improvement, disappearance of 
ascites and a decrease of liver volume.
Cyst growth is modulated by cAMP, which stimulates cholangiocyte proliferation 
and cyst fluid secretion, a process which is inhibited by somatostatin.4 In an animal 
model for polycystic liver disease, octreotide reduced hepatic cyst volume in a dose- 
dependent manner.5 In ADPKD, octreotide inhibited renal cyst growth by ~55%, 
but hepatic cyst volume was not evaluated in this trial.6
How does this effect compare with other therapeutic modalities for polycystic livers? 
We evaluated aspiration-sclerotherapy and laparoscopic fenestration for this indication 
and found that these achieve a volume reduction of 19.2% and 12.5%, respectively.3’7. 
Although somatostatin reduces the hepatic venous pressure gradient, this alone would 
be insufficient to ameliorate the intractable ascites.8 Therefore, we surmise that the 
therapeutic effect of octreotide results from direct reduction of hepatic cyst volume. 
In addition, this report implies that cystic fluid accumulation is a dynamic process 
which can be reversed by somatostatin analogues.
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Patients with polycystic livers develop symptoms due to the enlarged 
liver volume. Treatment aim s to reduce liver volume and are invasive with 
considerable morbidity. There is a clear and unmet need for medical therapy 
for polycystic livers. Experimental evidence suggests that octreotide reduces 
liver volume in a rodent model for polycystic liver disease. We evaluated 
treatment with octreotide in polycystic livers. Eight polycystic liver patients (1 
male with PCLD , 7 female with ADPKD; median age 48.1 years (IQR 40—68)) 
were treated with octreotide 100 m cg t.i.d. s.c. We measured change in liver 
and kidney volume by computer tomography (CT) scans, prior and following 
treatment. Median and interquartile ranges (IQR) were calculated and 
Wilcoxon signed rank test was used to calculate differences in liver volume 
before and after treatment. Median liver volume at baseline was 4786 m L 
(IQ R 2896—7895) and combined kidney volume 1483 m L (IQ R 741—1902). The 
median duration of treatment was 135 days (IQR 90—180). The median change 
in liver volume was -3.0% (IQR -7.6—0.0, p=0.069) and kidney volume -0.0% 
(IQ R -6.9—3.7, p=0.674). Liver enzymes remained unchanged. Side effects 
were common and most prevalent during the first 1-2 weeks and included 
diarrhea concomitant with pale stools, abdominal cramps, weight loss and 
hair loss. Patients considered the t.i.d. treatment schedule as very intensive 
and difficult to continue. Conclusions: Octreotide t.i.d. reduces liver volume, 
but not kidney volume. Patient acceptance of this intensive treatment is low, 
and after terminating treatment, liver volume increases again.
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Polycystic livers are present in the majority o f patients with autosomal dominant 
polycystic kidney disease (ADPKD).1 This disease is characterized by polycystic 
kidneys and is caused by mutations in PKD1 or PKD2.2 ADPKD is the most inherited 
renal disease. It occurs worldwide and in all races, with a prevalence estimated to 
be between 1:400 and 1:1000.3 Approximately 80% of ADPKD patients have a 
polycystic liver.1 By contrast, autosomal dominant polycystic liver disease (PCLD) 
is rather infrequent, and the presence of numerous cysts is limited to the liver only.4 
PCLD is caused by mutations in PRKCSH or SEC63. 5;6
Growth of cysts is an ongoing process, as the prevalence of liver cysts increases 
with age, and size of individual cysts enlarges in time.1 Polycystic livers are more 
common in women, which probably indicates a stimulatory role o f estrogens in liver 
cyst growth.1;7;8
Most patients with a polycystic liver are asymptomatic, but due to mass effect of 
the large polycystic liver, symptoms arise.9;10 Symptoms include abdominal distension, 
postprandial fullness, dyspnea and abdominal pain. Furthermore, the large liver can 
impair patients in their daily life activities.11 Rarely, complications, such as hemorrhage, 
rupture and infection of a cyst and portal hypertension, occur.9 
Treatment of polycystic livers is aimed to reduce liver volume and at this moment 
include invasive options such as aspiration-sclerotherapy, laparoscopic fenestration 
and liver transplantation.10;12-14 Unfortunately, not all patients are suitable for one of 
these therapeutic options and therefore there is a high demand for alternatives such 
as medical treatment.
In a time- and dose-dependent manner, octreotide reduced liver and kidney weights 
and inhibited growth of hepatic and renal cyst volume, in an animal model for 
autosomal recessive polycystic kidney disease (ARPKD), the polycystic kidney (PCK) 
rat.15
We found that a 3-6 month somatostatin analogue treatment o f two polycystic liver 
patients decreased liver volume by 38.3% and 14.9%.16 This stimulated us to evaluate 
the effect of octreotide in a large series of polycystic liver patients.
P a tie n ts  a n d  M eth o d s
In 2008, eight symptomatic patients (1 male, 7 female; median age 48.1 years (IQR 
40—68)) with a polycystic liver were treated with 100 mcg octreotide three times 
daily subcutaneously (Novartis Pharma Stein AG, Basel, Switzerland). The male 
patient was diagnosed with PCLD as he had only one cyst in the left kidney. The 
seven female patients were diagnosed with ADPKD as all of them had at least more
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than five cysts in both kidneys. None of the patients were on oral contraceptive or 
hormone replacement therapy.
To evaluate the effect of the treatment with octreotide, computed tomography (CT) 
scans were performed prior and after treatment. Assessment of liver volume and 
kidney volume in the ADPKD patients was performed as described before.13 In brief, 
after loading the CT scan into Pinnacle3® v8.0d (Philips Electronics NV, Eindhoven, 
the Netherlands), the liver outline was manually delineated in transverse slices every 
9 mm, and for the kidney outline every 6 mm. Software interpolated intermediate 
slices and after fine tuning of the interpolated contours the indicated circumferences 
were calculated for total liver and kidney volume.
As laboratory tests were performed in different laboratories, we calculated alanine 
transferase (ALT), alkaline phosphatase (AP) and gamma glutamyl transferase (GGT) 
to the upper limit of normal (ULN). Median and interquartile ranges (IQR) were 
calculated and Wilcoxon signed rank test was used to calculate differences in liver 
volume before and after treatment. All statistical analyses were undertaken with SPSS 
statistical software package version 16.0 (SPSS Inc., Chicago, IL, USA). All p-values 
calculated were two-tailed and the level o f significance was set at a=0.05.
R esults
Median liver volume at baseline was 4786 mL (IQR 2896—7895) and combined kidney 
volume 1483 mL (IQR 741—1902). Time interval between the first CT scan and start 
of treatment was 1.5 days (IQR 0—35.3). The liver synthesis capacity was normal in 
all patients. At baseline, the median laboratory results were normal for all parameters, 
except for gamma glutamyl transferase (GGT) which was clearly elevated (>2 times 
ULN) in 3/8 patients. The median duration of treatment was 135 days (IQR 90—180) 
(Table 8.1).
After treatment, the liver volume decreased with a median of 135 mL (IQR -272—21 
mL) to 4730 mL (IQR 2729—7793), a median change of -135 mL, which represents 
-3.0% (IQR -7.6—0.0, p=0.069). Six (75%) patients had a decrease o f liver volume, 
while two had an increase (Figure 8.1). Kidney volume remained unchanged (-0.8%; 
IQR -8.7—4.3, p=0.735). We did not find a correlation between duration of treatment 
and change in liver or kidney volume.
One of the patients, who had been treated for 180 days, had a CT-scan after 90 and 
180 days o f treatment. At baseline, her liver volume was 2432 mL, after 90 days of 
treatment it decreased to 2321 mL (-111 mL) and the following 90 days her liver 
volume decreased further with another 88 mL. After 180 days o f treatment, her liver 
volume was 2233 mL (-199 mL, -8.2%). The extent of the dynamics of the changes 
induced by octreotide is illustrated by another patient, where the 90-day treatment
Table 8.1 Patient characteristics
Pa­
tient
Sex Diagnosis Age*(years)
Length of 
treatment (days)
Liver volume 
before (mL)
Kidney volume 
before (mL)
GGT before 
(times ULN)
1 F ADPKD 50 70 4581 1816 2.1
2 F ADPKD 37 90 8547 791 1.0
3 M PCLD 80 90 5939 4.7
4 F ADPKD 45 90 4286 3006 1.2
5 F ADPKD 40 180 10174 1902 1.0
6 F ADPKD 71 180 2432 741 11.5
7 F ADPKD 39 180 4991 1483 1.5
8 F ADPKD 57 180 2145 678 1.0
'Reflects age at start of treatment; F, female; M, male; ADPKD, autosomal dominant polycystic kidney disease; PCLD, polycystic liver disease; 
GGT, y glutamyl transferase; ULN, upper limit of normal
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Figure 8.1 Liver volume before and after treatment
M edian d e c re a se  o f  liver vo lu m e o f 135 mL, which is 3.0 
p in g  trea tm en t with octreo tid e .
i (p=0 .069). *Liver v o lu m e a fter 3 m on th s o f  sto p-
reduced liver volume by 9.4%, but at 3 months follow-up, his liver volume had again 
increased to baseline.
Laboratory results remained unchanged during the treatment. Side effects were 
common and most prevalent during the first 1-2 weeks and included diarrhea with 
pale stools (n=6), abdominal cramps (n=3), weight loss (n=3) and hair loss (n=3). One 
patient was treated with pancreatic enzyme replacement therapy because of severe 
side effects with ready improvement. After 6 weeks she did not need the enzymes 
anymore and symptoms did not recur.
Patients considered the t.i.d. treatment schedule as very intensive and difficult to 
continue.
D iscu ssio n
This study allows us to make three important observations. First, treatment of 
patients with a polycystic liver with octreotide 100 mcg t.i.d. s.c. results in a median 
reduction of liver volume of 3.0%. Second, after stopping treatment cyst growth 
resumes, and finally, octreotide did not affect renal cyst volume. The results of this 
study are a clear departure from the natural history of cystic disease which suggests 
an unremitting growth with time.1;17
Octreotide in polycystic livers | 101
Until now, patients with a symptomatic polycystic liver are only treated by invasive 
treatments which is associated with significant morbidity. The clinical observation 
that the size o f renal cysts in a patient with ADPKD and acromegaly did not grow 
under treatment with octreotide, pointed to a possible role for somatostatin analogues 
in the treatment o f polycystic kidneys.18 The pilot study that followed demonstrated a 
slowed growth of kidney cysts during a 6-month treatment with long-acting octreotide. 
Data on effect of somatostatin analogues on liver cysts are scarce, but support for its 
use stems from experimental studies in rodents and a recent case report.15;16 These 
results must be viewed as the first step in the medical treatment o f polycystic livers 
and kidneys, but the result of our study supports the earlier observations in two 
cases. We observed a striking dichotomy in the effect o f short-acting octreotide on 
liver or kidney cysts. The volume reducing effect o f short-acting octreotide seems to 
be limited to the liver, as the volume of renal cysts remained unchanged during the 
course of the study. It is possible the effect o f octreotide on the renal cysts should be 
viewed as beneficial, and be interpreted as abrogated growth, as the natural history 
shows a continuous growth of renal cysts. The exact reason for this apparent paradox 
is unknown.
The volume reducing effect of octreotide from this series is smaller than in reported 
case reports. It is difficult to explain the difference, as dosage or duration of treatment 
was similar to the case reports.
The results of this trial also indicate that the volume reducing effect can be achieved 
quite rapidly, within 12 weeks, but that adherence to therapy is needed, as stopping 
results in recurrence. In this study, the median decrease o f liver volume per day can 
be estimated at 1 mL/day (135 mL /  135 days).
At this point we do not know whether the effect of octreotide is class specific shared 
by other somatostatin analogues or whether the effect is specific to octreotide. In 
addition, we do not know whether long-acting, once-a-month, octreotide therapy 
produces similar effects. Future trials should shed light on this issue.
The action of octreotide in the polycystic liver is mediated through somatostatin 
membrane receptors (sstr), which are present in the human kidney, human 
cholangiocytes and on liver cyst epithelia in the PCK-rat.15;19;20 After binding of a sstr, 
signaling cascades are activated through the inhibitory G (Gi) protein suppressing 
cAMP.21;22 This suppression of cAMP will diminish cell proliferation and fluid 
secretion of renal and hepatic cysts.15;21;23
Octreotide was well tolerated by all patients and there were no unexpected severe 
adverse events. Diarrhea, experienced by six patients, subsided spontaneously in 
two weeks, which is in line with the literature.22 Hair loss in three patients, slightly 
diminished during treatment or stopped after end of treatment.
This study has several limitations. We report treatment with octreotide in only eight 
patients. We cannot exclude that the changes observed fit with the natural history of
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the disease. On the other hand, we saw that continuous treatment was necessary to 
maintain the volume reducing effect and that the effect disappeared after stopping. 
All in all, 75% of patients responded to therapy. Furthermore, the decrease of liver 
volume did not reach statistical significance, although this is likely due to a type II 
error.
We did not include a control group, which limits the possibility of comparingthe 
measured effect with the natural course of the disease in patients that were not on 
treatment. Nevertheless, renal and liver cyst growth is an ongoing process,1;17;24 and 
without a therapeutic intervention there will be an increase of kidney and liver volume 
with time.
We did not observe significant changes o f symptoms with a standardized 
questionnaire. During the first four weeks of treatment, patients indicated a decrease 
in tense abdomen, less pain and more energy. During follow-up, symptoms remained 
stable, and the patients did not report further relief of symptoms. In one patient, 
we were able to observe liver volume at two time points during treatment (after 90 
and 180 days). During the first three months a decrease o f liver volume of 111 mL 
was measured, and during the next three months the decrease of liver volume was a 
further 88 mL. Although there was still a decrease, it was less in the second period of 
90 days compared with the first. There was recurrence of symptoms after 2-4 weeks. 
Three months of follow-up in one patient showed an increase o f liver volume to 
baseline again. This suggests that cysts expand again after treatment with octreotide 
is stopped, which would argue for a continuous treatment with octreotide, at least to 
maintain the effect of treatment.
A drawback of the treatment with octreotide 100 ^g t.i.d. s.c. was the intensive t.i.d. 
treatment regimen. Patients experienced it as very intensive, it made an impact on 
their daily routine as they were confronted with their disease several times a day. 
Nevertheless, the compliance was good. The use o f a long-acting somatostatin should 
be considered when offering patients this type of treatment.
All in all, the result of this study provides a rationale for a randomized controlled 
trial to evaluate the effect of octreotide as treatment of polycystic livers and kidneys.
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Therapy for polycystic liver is invasive, expensive, and has disappointing long­
term results. Treatment with somatostatin analogues slowed kidney growth in 
patients with polycystic kidney disease (PKD) and reduced liver and kidney 
volume in a PKD rodent model. We evaluated the effects of lanreotide, a 
somatostatin analogue, in patients with polycystic liver because of autosomal­
dominant (AD)PKD or autosomal-dominant polycystic liver disease (PCLD). 
We performed a randomized, double-blind, placebo-controlled trial in 2 
tertiary referral centers. Patients with polycystic liver (n=54) were randomly 
assigned to groups given lanreotide (120 mg) or placebo, administered every 
28 days for 24 weeks. The primary end point was the difference in total liver 
volume, measured by computerized tomography at weeks 0 and 24. Analyses 
were performed on an intention-to-treat basis. Baseline characteristics were 
comparable for both groups, except that more patients with ADPKD were 
assigned to the placebo group (^=0.03). The mean liver volume decreased 2.9%, 
from 4606 m L (95% CI 547—8665) to 4471 m L (95% CI 542—8401), in patients 
given lanreotide. In the placebo group, the mean liver volume increased 1.6%, 
from 4689 m L (95% CI 613-8765) to 4895 m L (95% CI 739-9053) (p<0.01). Post 
hoc stratification for patients with ADPKD or PCLD  revealed similar changes 
in liver volume, with statistically significant differences in patients given 
lanreotide (^<0.01 for both diseases). Conclusions: In patients with polycystic 
liver, 6-months of treatment with lanreotide reduces liver volume.
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Polycystic liver represents a late stage o f disease that is common to two inherited 
disorders: autosomal dominant polycystic kidney disease (ADPKD) and autosomal 
dominant polycystic liver disease (PCLD). ADPKD is the most common inherited 
nephropathy and the second most common inherited syndrome, affecting an 
estimated 0.2% of the population.1 O f ADPKD patients, 58% in 15—24 years o f age, 
85% in 25—34 years of age, and 94% in 35—46 years of age suffer from polycystic liver 
in addition to polycystic kidneys.2 ADPKD is caused by gene mutations in PKD1 
and PKD2.3-4 By contrast, polycystic kidneys are lacking in patients with PCLD, an 
infrequent inherited disorder caused by mutations in PRKCSH and SEC63.5-6 
The natural history of the disease suggests a continuous increase with age in the 
volume of the affected polycystic liver.2 This is in part due to an increase with age 
in the number of hepatic cysts,7 but also because the individual cyst volume grows 
from 0.25 mL to 22.8 mL over 10 years.8 There is a gender disparity as cross-sectional 
studies in ADPKD have indicated that total liver cyst volume is significantly greater 
in women than in men.2-9
Symptoms in polycystic liver arise from enlarged liver volume, and include abdominal 
distension, early satiety, dyspnea, and pain.4;10;11 In addition, polycystic liver may be 
complicated by cyst bleeding, infection and/or rupture.12
Current therapeutic options aim to reduce liver volume and include a variety of 
surgical procedures such as aspiration-sclerotherapy, laparoscopic or laporotomic 
fenestration, and partial liver resection.4-13-14 The drawbacks common to all o f these 
procedures are their only partial effectiveness, their invasive nature, and their related 
morbidity and mortality. Most importantly, they do not change the natural course 
of the disease because symptoms recur because o f growth of new cyst or regrowth 
of treated cysts.12 Consequently, there is a clear unmet need for other therapeutic 
options.
Liver cysts arise from cholangiocytes,15 and its fluid homeostasis appears to be dynamic 
in nature, because secretin increases the fluid secretion in hepatic cysts.16 Secretin is a 
potent stimulator of adenylate cyclase, which converts adenosine triphosphate (ATP) 
to cyclic adenosine monophosphate (cAMP). cAMP acts as second messenger in the 
intracellular signal transduction and stimulates cyst growth by two major mechanisms: 
increase of release o f electrolyte and water secretion from biliary epithelial cells17 and 
stimulation of cholangiocyte proliferation.18-19 Somatostatin inhibits fluid secretion 
and proliferation by reducing cAMP in cholangiocytes.17-20 In a rodent model for 
polycystic liver, the polycystic kidney (PCK) rats, administration of octreotide, a 
somatostatin analogue, prevented outgrowth of liver and kidney cysts.21 
A 3- to 6-month treatment with somatostatin analogues in two patients with 
polycystic liver led to impressive reductions in liver volume of 38.3% and 14.9%,
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respectively.22 This success stimulated us to assess the effect of the long-acting 
somatostatin analogue lanreotide in patients with polycystic liver because o f either 
ADPKD or PCLD. To this end, we initiated a multicenter, randomized, double-blind, 
placebo controlled trial: the Long-acting lanreotide as a volume reducing treatment 
of polycystic livers (LOCKCYST) trial.
M a ter ia ls  a n d  M eth o d s
Patients
This study was performed in Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands and University Hospital Gasthuisberg, Leuven, Belgium. 
Men and women aged 18 years and older, with more than 20 liver cysts revealed by 
computerized tomography (CT) scan, were enrolled. Use of oral contraceptives or 
estrogen supplementation was not allowed. Additionally, patients were excluded if they 
were pregnant or breast-feeding; had symptomatic gallstones; required hemodialysis; 
had a history of or other severe illnesses that would make that patient unsuitable for 
the study. ADPKD was diagnosed in case more than five kidney cysts in either one 
or both kidneys were visible on CT; otherwise, the patient was diagnosed with PCLD.
Ethical issues
The protocol was approved by the institutional review boards of the participating 
institutions according to their national guidelines, and the study was performed 
according the Declaration of Helsinki and international standards of good clinical 
practice. All patients provided written informed consent. The trial was registered 
at clinicaltrials.gov (NCT00565097). CONSORT guidelines were followed for the 
reporting of the study.23
Study design and outcome measures
Randomization numbers were generated using the SAS RANDO (SAS Institute 
Inc., Cary, NC) randomization tool. Randomization was performed by an unblinded 
investigational pharmacist in blocks o f four and the two treatment arms were allocated 
in a 1:1 ratio within each block. Participants and investigators were blinded to group 
assignment until database lock. Study medication was assigned to each participant 
according to the randomization code either to the long-acting somatostatin analogue, 
lanreotide autosolution 120 mg, or to placebo (containing normal saline) administered 
subcutaneously (sc) every 28 days for 24 weeks. Physicians performing the assessments 
and patients were unaware of treatment assignment. Active drug and placebo were 
administered by independent physicians/nurses. Unblinding of investigators and 
participants was performed after all data collection was finished.
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The primary endpoint was change in liver volume measured on CT scan at baseline 
and after 24 weeks of treatment. Secondary endpoints were change in kidney volume in 
ADPKD, change in abdominal symptoms and health-related quality of life (HRQoL), 
assessed on the same time points. Type and severity of gastrointestinal symptoms, 
that is, abdominal and epigastric pain, regurgitation, heartburn, and loss of appetite, 
were assessed on a valid seven-point adjectival scale.24 HRQoL was assessed using the 
Medical Outcomes Study Form 36 (SF-36),25 which comprises nine minor domains 
(physical functioning, social functioning, physical role functioning, emotional role 
functioning, mental health, vitality, bodily pain, change in health perception and 
general health perception), which can be summarized into a physical and a mental 
component. Lower scores indicate worse HRQoL.
Safety analyses were performed for all patients. Standard clinical and laboratory tests 
were performed at baseline, week 4, week 12 and week 24.
CT scanning and 3D volumetry
CT scans at baseline and week 24 were performed on a multidetector CT scanner 
(Somatom Sensation 16 or 64, Siemens Medical Solution AG, Erlangen, Germany) 
(Supplementary Figure 9.1). All CT scans were blinded to patient identity and date 
of birth as well as date of scan. In random order, measurements of liver and kidney 
volume in ADPKD patients were performed as previously described.14 Unblinding of 
CT scans was performed after all liver and kidney volumes were measured.
Lanreotide serum levels
Lanreotide serum levels were measured at week 0 and week 12 in patients who received 
lanreotide in the Radboud University Nijmegen Medical Center. Blood samples were 
taken prior to injection at weeks 0 and 12 for measurement o f minimum lanreotide 
serum levels at 12 weeks (Cmin) with baseline as a reference. Serum concentrations of 
lanreotide were determined using a validated radioimmunoassay method as described 
before.26
Statistical analysis
Sample sizes were determined prospectively with reference to two previous (pre) 
clinical studies that used similar end points.21;27 We hypothesized detection of a 
difference (effect size) of 50 percentage points between response rates in the two 
groups (30% in the placebo group; 80% in the lanreotide) for the primary outcome. 
For a statistical power of 80% and a probability of a type I error of 0.05 using a 
two-sided test, we calculated that the sample size for this trial should be at least 38 
patients (19 per group). Taking into account the possibility of protocol violation and/ 
or dropouts, we aimed at inclusion of 27 patients per group.
Statistical analysis was performed on an intention-to-treat analysis, defined as
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all randomly assigned patients who received at least one dose o f  study drug. For 
continuous data, Student t test was used to calculate differences between groups for 
normally distributed data or M ann Whitney U  test for non-normally distributed data. 
The Pearson Chi-Squared test was used to compare dichotomized outcomes between 
the groups. All statistical analyses were undertaken with SPSS statistical software 
package version 16.0 (SPSS Inc., Chicago, IL , USA). All ^ -values calculated were tw o­
tailed and the level o f  significance was set at a=0.05.
R esults
Baseline characteristics
A  total o f  113 consecutive patients with polycystic liver were assessed during the study 
period. O f  these, 56 patients declined to participate, and three patients were excluded 
as they did not fulfill the inclusion criteria. Between O ctober 2007 and February 2008, 
the remaining 54 patients were randomly assigned to receive lanreotide 120 m g or 
placebo sc every 28 days. Baseline characteristics are shown in Table 9.1. One female 
patient, who was randomly assigned to placebo, withdrew after 14 weeks o f  the study, 
because she was diagnosed with breast carcinoma. One patient on lanreotide omitted 
the injection at week 4, because he experienced very severe diarrhea and abdominal 
cramps. One patient on placebo did not receive injection 6 (at week 20) (Figure 9.1). 
The treatment group and placebo group were similar for m ost characteristics, except 
for the genetic background (A D P K D  versus P C LD ), and relatively more P C LD  
patients (68%) than A D P K D  patients (38%) received lanreotide.
Table 9.1 Demographics and baseline clinical characteristics
Lanreotide group 
(N=27)
Placebo group 
(N=27) p
Age (years) 49.6 (34.4-64.8) 50.3 (32.6-68.1) 0.752
Sex (male/female) 3/24 4/23 0.685
Diagnosis (ADPKD/PCLD) 12/15 20/7 0.027
Centre (Leuven/Nijmegen) 12/15 12/15 1.000
Body mass index (kg/m2) 26.1 (18.7-33.5) 25.7 (18.6-32.8) 0.733
Liver volume (mL) 4606 (547-8665) 4689 (613-8765) 0.698
Right and left kidney volume (mL)* 1000 (-39-2039) 1115 (-519-2748) 0.673
D ata a re  m ean  (95% CI); ADPKD, au to so m a l do m in an t po lycystic  kidney d ise a se ; PCLD, po lycystic  liver 
d ise a se ; *O nly ADPKD p atien ts
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Figure 9.1 Trial profile
Liver volume
The mean liver volume decreased from 4606 mL (95% CI 547—8665) to 4471 mL 
(95% CI 542-8401) in patients assigned to 6-month treatment with lanreotide, an 
average reduction of 2.9% (95% CI -11.1-5.4). In contrast, patients in the placebo 
group had an increase in mean liver volume from 4689 mL (95% CI 613-8765) to 
4896 mL (95% CI 739-9053), an average increase of 1.6% (95% CI -5.2-8.4) over 
the same time span (Table 9.2). The difference in change in liver volume between 
treatment arms was statistically significant (p<0.01). O f patients on lanreotide, 85% 
showed a decrease of liver volume, compared with 27% of patients receiving placebo 
(Figure 9.2). There was a correlation between liver volume at baseline and response to 
treatment: we saw that larger livers had proportionally more volume reduction than 
smaller livers (r= -0.42, p=0.032).
Next, we explored whether genetic cause of the disease affected the primary outcome. 
We performed post hoc stratification using ADPKD and PCLD as variables. The 
change in liver volume was similar in both groups and independent of cause of 
disease, and, for both disorders, differences between placebo and lanreotide were 
statistically significant (both p<0.01) (Table 9.2).
Table 9.2 Outcomes
Lanreotide Placebo
Diagnosis Baseline End Absolutechange Baseline End*
Absolute
change*
"  P
Liver volume (mL)
4606 4471 -134 4689 4896 92
Doth
(547-8665) (542-8401) (-476-207) (613-8765) (739-9053) (-320-504)
-2.9% (-11.1-5 •4) 1.6% (-5.2-8.4)
Liver volume (mL) 4195 4138 -57 3855 4428 2131 _)
(437-7952) (462-7814) (-337-223) (-338-8047) (-140-8996) (-268-695)
-1.1% (-7.3—5.i0) 3.8% (-3.9-11.4)
Liver volume (mL) 5119 4888 -231 4981 5036 55A U l i V U
(762-9476) (645-9130) (-555-93) (1000-8963) (925-9148) (-318—428)
-5.0% (-13.8-3 •7) 9.9% (-5.2-7.2)
Kidney volume (mL)
1000 983 -17 1115 1165 50 n  m  qA U l i V U
(-39-2039) (-62-2028) (-126-93) (-519-2748) (-541-2870) (-99-199)
U .U lo
-1.5% (-13.2-10.3) 3.4% (-7.1-14.0)
Data are mean (95%CI); ADPKD, autosomal dominant polycystic kidney disease; PCLD, polycystic liver disease; *Not of all patients end data available: baseline 
n=27, end n=26 .
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Figure 9.2 Absolute change in liver volume in all patients
Each bar rep re se n ts o n e  p atien t (n=53)
Kidney volume
We assessed volume of polycystic kidneys in ADPKD patients. Combined mean 
kidney volume decreased from 1000 mL (95% CI -39—2039) to 983 mL (95% CI 
-62—2028), a decrease of 1.5% (95% CI -13.2—10.3) in patients treated with lanreotide. 
In contrast, mean kidney volume increased from 1115 mL (95% CI -519—2748) to 1165 
mL (95% CI -541—2870) (3.4%; 95% CI -7.1—14.0) in the placebo group. Again, the 
treatment differences in volume change were statistically significant (p=0.02) (Table 
9.2).
Laboratory results
Baseline laboratory results did not differ between treatment arms. Liver synthesis 
capacity was normal in all patients during the study. Biochemical and haematological 
changes during the trial were comparable between groups with the exception of 
y-glutamyl transferase (GGT) levels (Table 9.3). Treatment with lanreotide led to 
a significant increase in GGT levels at t=24 weeks compared with placebo. The 
difference was significant within the individual treatment arms (p=0.03) as well 
as between placebo and lanreotide (p=0.03). We were interested in the effect of
Table 9.3 Laboratory results
Lanreotide Placebo
Baseline End Absolutechange Baseline End*
Absolute
change*
Creatinine ((imol/L) 83 (8-158) 80 (8-153) -2 (-20-15) 91 (9-173) 96 (-12-205) 4 (-29-38)
AST (U/L) 29 (-16-74) 31 (-10-73) 2 (-15-19) 23 (8-39) 28 (8—48) 4 (-13-21)
ALT (times ULN) 1.1 (0.2-2.1) 1.1 (0.3-2.0) -0.0 (-0.5-0.5) 1.1 (0.6-1.6) 1.1 (0.3-1.9) 0.0 (-0.8-0.8)
Alkaline phosphatase (times ULN) 1.3 (-0.0-2.5) 1.4 (-0.6-3.3) 0.1 (-0.7-1.0) 1.0 (0.9-1.2) 1.0 (0.8-1.3) 0.0 (-0.1-0.1)
y Glutamyl transferase (times ULN) 3.4 (-3.6-10.4) 4.L+ (-5.2-13.3) 0.7t* (-2.2-3.5) 2.5 (-2.5—1.6) 2.5 (-2.0-7.0) -0.1 (-1.7-1.6)
Bilirubin (jimol/L) 10 (-3-23) 11 (-1-23) 1 (-8-9) 10 (1-18) 11 (2-20) 2 (-6-9)
Albumin (g/L) 43 (34-51) 44 (37-52) 2 (-3-6) 43 (36-50) 44 (36-52) 1 (-4-5)
Data are mean (95% Cl); 'Not of all patients end data available: baseline n=27, end n=26; fp<0.01 vs baseline; *p=0.03 vs placebo; AST, aspartate aminotransfer­
ase; ALT, alanine aminotransferase; ULN, upper limit of normal.
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lanreotide on renal function and assessed serum creatinine levels. In comparison 
with placebo, we found that lanreotide treatment decreased serum creatinine levels, 
although this did not reach statistical significance (p=0.079).
Gastrointestinal Symptoms and Health-Related Quality of Life
We observed no significant changes in gastrointestinal symptoms (Supplementary 
Table 9.1). A single subdomain score o f the HRQoL questionnaire (SF-36), that is, 
current health perception, improved significantly from 42 (95% CI -11—94) to 62 
(95% CI 18—106) in patients treated with lanreotide (p<0.01) and this change was also 
significant (p<0.01) compared with placebo where values remained stable (43 (95% 
CI -4—90) to 41 (95% CI 4—78)). No other HRQoL subdomains changed over the 
course of the study (Supplementary Table 9.2).
Adverse events
There were no severe adverse events related to the study medication. No important 
changes occurred in the monitored laboratory parameters (Table 9.3), and no changes 
in body weight were observed. The most common adverse effect consisted of loose, 
pale, and fatty stools (19 patients), which typically started 24 hours after first injection 
of lanreotide and lasted for 1—4 days (Table 9.4). Six patients were treated with 
pancreatic enzymes, which readily improved the symptoms. Thirteen patients (48%) 
on lanreotide reported nodules on the injection site.
Table 9.4 Adverse events
Adverse event Lanreotide n /N * (%) Placebo n /N * (%)
Digestive tract
Diarrhoea 19/27 (7G) 3/27 (11)
Pale stools 11/27 (41) G/27 (G)
Abdominal cramps 14/27 (52) G/27 (G)
Flatulence 2/27 (7) G/27 (G)
Constipation 1/27 (4) G/27 (G)
Other
Nodules at injection side 13/27 (48) G/27 (G)
Rash 2/27 (7) G/27 (G)
Breast carcinoma G/27 (G) 1/27 (4)
*D en om in ators is total o f  p atie n ts  in stu d y  arm
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Lanreotide serum levels
Lanreotide measurements were performed in 30 samples at two time points for 
15 patients. At baseline, lanreotide concentration was below the lower limit of 
quantification (0.078 ng/mL). At week 12, mean lanreotide concentration had risen 
to 3.36 ng/mL (95% CI 0.53-6.18).
There was no correlation between lanreotide serum level and response to treatment, 
suggesting that the achieved serum levels surpassed the treatment threshold.
D iscu ssio n
Our results demonstrate that injections o f lanreotide 120 mg given once a month for 
six months result in a significant mean reduction of liver volume of 134 mL (2.9%) in 
patients with polycystic liver. The improvement was independent of genetic cause of 
the polycystic liver, because PCLD and ADPKD patients benefited similarly, but we 
observed that larger livers benefited most. In contrast, patients who received placebo 
ran an unfavourable course with a mean increase of liver volume of 1.6% over six 
months. Moreover, lanreotide improved the general health perception of patients 
with polycystic liver at six months.
Although it was not the primary purpose of our study to demonstrate that lanreotide 
had extrahepatic beneficial effects, we saw an improvement in the renal phenotype 
in ADPKD. At six months, the volume of polycystic kidneys had grown by 3.4% 
in the placebo group but decreased by 1.5% with lanreotide, a difference of 4.9% 
at six months. Data from a large observational trial, the Consortium for Radiologic 
Imaging Studies in Polycystic kidney disease (CRISP) study,8 indicate that kidney 
volume in ADPKD patients at high risk for renal insufficiency increases annually by 
5.3%. We studied a population with milder ADPKD: despite this difference, average 
size o f polycystic kidneys at baseline (~1000 mL) and average growth in ADPKD 
patients on placebo (3.4% per 6 months) is comparable with the average size and 
annual growth seen in the CRISP study.
We had several reasons to select somatostatin analogues as a therapeutic option 
in polycystic liver. It is known that somatostatin receptors are expressed on 
cholangiocytes and rodent liver cyst epithelia.20;21 After binding to these somatostatin 
receptors, somatostatin activates signalling cascades through the inhibitory G (Gi) 
protein, which suppresses cAMP. cAMP appears to be an important stimulator of 
fluid secretion and cell proliferation of renal cysts in ADPKD28 and also of liver cysts 
in appropriate rodent models.21 A randomized study in ADPKD patients studied 
the effect of slow-release octreotide 40 mg or placebo on polycystic kidney volume.27 
Octreotide possessed a treatment advantage by reducing kidney volume increase by 
60% at 6 months compared with placebo, but there was still an ongoing increase of
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kidney volume in both groups (2.2% octreotide; 5.9% placebo). This contrasts with 
our study in which long-acting lanreotide resulted in a decrease o f kidney volume by 
1.5%. It is unclear whether a distinct pharmacokinetic and pharmacodynamic profile 
explains the differences. We treated our patients with lanreotide 120 mg, which is 
equivalent to octreotide 60 mg, suggesting that higher serum levels were probably 
present in our study.29 In contrast, somatostatin receptor affinity o f octreotide is 
higher compared with that of lanreotide, which may offset the higher serum levels.30 
Lanreotide was well tolerated in all patients. We did not observe any unexpected 
severe adverse events.31-33 The most commonly reported adverse event was diarrhea 
associated with abdominal cramps. Symptoms improved over the course of a few days 
and stopped after repeated injections or after administration of pancreatic enzymes. 
Gluteal nodules following injection were reported in 48% of patients.
At baseline, GGT was elevated in both groups. During treatment with lanreotide, 
GGT increased further. GGT is a component on the brush border o f hepatic cyst 
epithelium and it is thought to be released in case of cyst epithelium degeneration.16 
This could be a possible explanation for the elevation of GGT in the treated group. 
How do results from this study compare with other treatment modalities? A recent 
case series noted that aspiration and sclerosis of individual liver cysts reduced liver 
volume by 19%.13 However, these were patients with one or more large dominant 
liver cysts, whereas most patients with a polycystic liver have widespread disease that 
is not amenable to this therapy. Alternatively, (laparoscopic) fenestration might be 
used as an option.14;34-37 The risk/benefit ratio of this procedure is suboptimal with 
a moderate reduction of liver volume (12.5%) and high complication risk (0—33%). 
This study comes with several limitations. We excluded patients requiring 
haemodialysis because of renal failure. There was a slight decrease of serum 
creatinine in patients treated with lanreotide compared with placebo, suggesting a 
beneficial effect on renal function. As patients had a relatively well-preserved renal 
function, we do not expect large changes in glomerular filtration rate. On the other 
hand, another randomized study with octreotide witnessed an increase o f serum 
creatinine and glomerular filtration rate in ADPKD patients.27 Again, this might be 
due to differences in the pharmacologic profile of the two drugs but also because 
patients in the octreotide trial had worse renal function from the outset. The nature 
of this study did not allow us to assess long-term safety. Nevertheless, we did not 
observe any new types of adverse events compared with other randomized trials with 
lanreotide.32 We chose a 6-month treatment regimen, and it is unclear whether a longer 
treatment would have demonstrated better results; experiments in a rodent model for 
polycystic disease suggest that the beneficial effects o f somatostatin analogues are 
time- and dose dependent.21 This suggests that longer treatment might result in more 
substantial effects. Indeed, prolonged lanreotide administration is feasible, because 
long-term studies in patients with acromegaly have shown that treatment up to 4
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years is well tolerated.32 Furthermore, little is known about the optimal dosage of 
somatostatin analogues. We chose for the highest licensed dose o f lanreotide at 120 
mg. In addition, it is not known whether the observed effect in this study is reversed 
after discontinuation of the drug, or in case of continuation, lanreotide becomes less 
effective.
This study demonstrates that lanreotide is able to change the natural disease course of 
polycystic livers in ADPKD and PCLD. The modest effect calls for further clinical 
trials, prior to adoption into clinical practice.
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Supplementary figure 9.1 Scatter-plots showing correlation between intra-observer
(A) and interobserver (B)
Briefly, a fte r  load in g  th e  CT scan  into Pinnacle3® v8 .0d  (Philips E lectron ics NV, E indhoven, th e  N etherlands), 
th e  liver ou tlin e  w as m an ually  d e lin eated  in tran sv e rse  slices every  9 or 10 m m , and  for th e  kidney outline 
every  5 or 6  m m . S o ftw are  in terp o lated  in term ed iate  slices a n d  a fte r  fine-tuning o f  th e  in terpo lated  con tou rs 
th e  in d icated  c ircu m feren ces w ere  ca lcu lated  for total liver an d  kidney vo lu m e. We v a lidated  our resu lts by 
usin g a seco n d  in d e p en d en t and  non se lec tiv e  se t  o f  CT scan s from  PCLD and  ADPKD p atien ts. M easu re­
m en ts o f  liver an d  kidney v o lu m e w ere  p e rfo rm ed  tw ice in a b lin d ed  m an n er by th e  sa m e  research er (L.vK). 
We ca lcu lated  th e  P earson  correlation  for th e  in traobservability , which w as exce llen t (r=0.998, p<0.01). N ext, 
an o th er  validation  step  w as in trod uced  a s  a qu ality  m easu re , and  v o lu m e s w ere  d eterm in ed  in d ep en d en tly  
by a seco n d  o b se rv e r  (R.V.) usin g S iem en s V olum e so ftw a re  (Siem en s M edical So lu tion s, Erlangen, G erm any). 
The liver w as outlin ed  m an ually  every  3 or 5 m m  w ith ou t interslice in terpolation  o f th e  e d g e s .  B e cau se  the 
so ftw are  is b a se d  on  H ounsfield  Units (HU; d en sities), th e  fo llow ing th resh old  se tt in g s  w ere  u sed : -15 HU to 
+  125 HU for u n en h an ced  CT scan s, 15 HU to  +  195 HU for con tra st-en h an ced  CT scan s. We ca lcu lated  the 
in terobserver correlation  by th e  Pearson  correlation , w hich w as exce llen t a s  well (r=0.994, p<0.01).
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Supplementary table 9.1 Severity of abdominal sym ptom s and mean VAS score
Lanreotide Placebo
Baseline 
n /N  (%)*
End
n /N  (%)*
Baseline 
n /N  (%)*
End
n /N  (%)*
Abdominal pain
In common 10/27 (37) 9/27 (33) 8/26 (31) 6/26 (23)
Postprandial 12/26 (46) 8/27 (30) 9/27 (33) 8/26 (31)
Fasting 8/26 (31) 6/27 (22) 9/27 (33) 5/26 (19)
Unrelated to defecation 6/26 (23) 7/27 (26) 6/27 (22) 6/26 (23)
Epigastric
In common 13/27 (48) 8/26 (30) 13/26 (50) 13/26 (50)
During daytime 12/26 (46) 10/27 (37) 13/27 (48) 13/26 (50)
At night/asleep 9/26 (35) 4/27 (15) 11/27 (41) 11/26 (42)
Heartburn 9/27 (33) 4/27 (15) 8/27 (30) 4/25 (16)
Regurgitation 12/27 (44) 6/27 (22) 12/27 (44) 9/26 (35)
Nausea 6/27 (22) 6/27 (22) 8/27 (30) 10/26 (38)
Vomiting 4/27 (15) 1/27 (4) 3/27 (11) 2/26 (8)
Loss o f appetite 10/27 (37) 9/27 (33) 8/27 (30) 6/26 (23)
Postprandial fullness 15/27 (56) 16/27 (59) 21/27 (78) 19/26 (73)
Shortness o f breath 12/27 (44) 14/27 (52) 15/27 (56) 14/26 (54)
Abdominal distension 16/27 (59) 14/25 (56) 18/27 (67) 14/26 (54)
Involuntary weight loss 4/27 (15) 6/27 (22) 4/27 (15) 3/26 (12)
VAS scoref 21 (-23-66) 22 (-27-71) 20 (-16-57) 25 (-23-73)
A bdom in al sy m p to m  severity  >  2 on a sev en -p o in t ad jectiva l sca le  ran g in g  from  0 to  6. VAS, visual a n a lo g u e  
scale ; sco red  on a ran g e  o f 0 -1 0 0  (0, no pain; 100, w orst pain); "D en om in ators d e p e n d  on th e  n u m ber o f  p a ­
tien ts w ho provided  an  an sw er for a specific  q u e stio n  in th e  q u estio n n aire ; i D ata are  m ean  (95% CI).
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Supplementary table 9.2 Mean Health-Related Quality of Life scores (SF-36)
Lanreotide Placebo
Baseline End Baseline End
Physical functioning 64 (6-123) 69 (15-123) 64 (21-107) 61 (21-101)
Social functioning 75 (24-126) 78 (27-129) 74 (20-128) 77 (29-125)
Physical role functioning 54 (-33-140) 65 (-21-151) 55 (-30-139) 51 (-40-142)
Emotional role functioning 86 (31-142) 74 (-4-152) 78 (7-150) 80 (9-151)
Mental health 75 (43-107) 72 (36-108) 74 (42-107) 74 (40-109)
Vitality 54 (8-100) 55 (17-93) 50 (7-93) 50 (15-86)
Bodily pain 22 (-4-49) 24 (4-45) 24 (3-45) 22 (-2-46)
Change in health perception 42 (-11-94) 62 (18-106) *t 43 (-4-90) 41 (4-78)
General health perception 53 (12-94) 59 (20-97) 48 (4-93) 48 (11-84)
Physical component summary 54 (12-95) 58 (14-97) 53 (14-92) 52 (4-78)
Mental component summary 69 (35-102) 67 (26-109) 66 (23-108) 66 (15-88)
D ata are  m ean  (95% CI). Scored  on a ran g e  o f 0 -1 0 0  (0= w o rst im agin ab le , 1 0 0 = b e st  im agin ab le). *p<0.01 vs 
b ase lin e  fp<0.01 vs p laceb o .
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Treatment o f polycystic livers
Polycystic livers are diagnosed when numerous fluid-filled cysts scattered 
throughout the liver parenchyma are observed at abdominal imaging. The 
natural course of the disease is an ongoing growth of the cysts and development 
of new cysts. Hepatic synthetic capacity is preserved. Polycystic livers are more 
prominent in women. Symptoms arise owing to m ass effect of the polycystic 
liver. Complications are uncommon. Treatment, in symptomatic patients, is 
invasive and aimed to reduce liver volume. This review describes the different 
therapeutic options: aspiration-sclerotherapy, laparoscopic fenestration, partial 
liver resection and liver transplantation. It gives a suggestion for treatment 
strategy. Furthermore, the upcom ing non-invasive therapeutic options are 
discussed. These developments are possible due to the identification of 
pathways involved in cyst development and growth.
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The diagnosis of polycystic livers is based on the finding of numerous fluid-filled 
cysts scattered throughout the liver parenchyma. Although of biliary epithelial 
origin, the cysts have no connections to the bile ducts.1 A polycystic liver is part of 
the phenotype in two distinct inherited diseases.2 Autosomal dominant polycystic 
kidney disease (ADPKD), caused by mutations in PKD1 or PKD2, is characterized 
by polycystic kidneys.1 However, most patients with ADPKD also have a polycystic 
liver as part of the phenotype and in a few the polycystic liver is the main cause of 
symptoms. Polycystic liver disease (PCLD), caused mainly by mutations in PRKCSH3 
or SEC63,4 is characterized by the presence of an isolated polycystic liver.
Although rare, at time of diagnosis it is important to exclude any tumours, including 
cystadenoma or cystadenocarcinoma. Differentiating polycystic liver from 
malignancies is possible by computer tomography (CT) scan and magnetic resonance 
imaging (MRI). Thick cyst walls and multilobular cysts are likely to indicate 
cystadenoma or cystadenocarcinoma.5 It should be recognized, however, that 
polycystic liver itself is not associated with increased risk of developing malignancy. 
The diagnosis of polycystic liver is usually made during the third and fourth decade 
of life. The disease has a progressive natural course, with ongoing growth of the 
cysts. Hepatic synthetic capacity is preserved in the great majority of patients.2 It is 
known that oestrogens stimulate cyst growth with the disease more prevalent and 
prominent in women. Its course, however, cannot be predicted in an individual.1’2 
Only a minority of patients develop massive polycystic livers with a severe course of 
disease.
Symptoms, such as abdominal distension, postprandial fullness and dyspnoea, arise 
owing to mass effect of the polycystic liver.1-3 Complications, mostly without clear 
cause, are uncommon, and include, in a chronological way of occurrence, bleeding, 
rupture and infection.1’2
Treatment is initiated only in those with symptoms and all interventional procedures 
are aimed at reducing liver volume.2’3 The choice o f treatment is based on size, location 
and number of the liver cysts, and on total liver volume (Figure 10.1).
I n v a siv e  t h e r a p eu t ic  o p tio n s
Aspiration-sclerotherapy
The primary and least invasive therapeutic option is aspiration-sclerotherapy. Under 
local anaesthesia, one or several cysts can be punctured under ultrasound or CT 
guidance and aspirated until all cyst fluid is evacuated.6 To prevent immediate 
recurrence of the cyst, exposure to a sclerosant for at least 10-15 minutes is needed.
I n tr o d u c tio n
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Figure 10.1 Suggested algorithm in the treatment of patients with a polycystic liver
This destroys the secretory and proliferation capacity of the cyst wall epithelium. The 
quantity of sclerosant should be at least 10% of the aspirated cyst fluid (to a maximum 
of 100 mL). Aspiration without sclerosant always results in recurrence of the cyst. 
The usual sclerosant is 95%—99% alcohol solution. Other sclerosants include several 
antibiotics. All of these agents are safe and effective. Retreatment o f a recurrent cyst 
may also be carried out, but the procedure is mainly used to treat new large cysts. In 
the authors experience of over 170 treatment sessions only two episodes of bleeding 
have occurred after aspiration-sclerotherapy (partially published in 6). This reflects 
the general literature where complications of this procedure also appear limited. The 
most suitable cysts for this form of therapy are dominant, strategically located, cysts 
with a diameter of over 6 cm.
Laparoscopic fenestration
Fenestration is the technique in which cysts are aspirated and deroofed in order to 
achieve volume reduction.2 Fenestration is a more radical technique than aspiration-
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sclerotherapy; numerous cysts may be treated during the same procedure. Since the 
introduction of laparoscopy, there has been a preference for this approach above 
laparotomic fenestration because o f lower rates of morbidity and mortality, and 
shorter hospital stay. With laparoscopy, the view of liver segments VII and VIII 
may be limited, and cysts located in this area cannot always be fenestrated.2’7 The 
complication rate ranges from 11—50%; most complications occur when deeper 
seated cysts are treated.2 Complications include bleeding, biliary leakage, ascites and 
pleural effusion.7 In the literature, around 280 fenestration procedures have been 
described with only one death.8
Partial liver resection
When the above methods have proved unsuccessful, the next option to reduce 
liver volume is partial liver resection; this may be a most difficult procedure. It is 
generally performed in combination with fenestrations.2 In massive polycystic livers, 
cysts are scattered throughout the whole liver parenchyma. All liver segments are 
affected and immensely enlarged, making the decision to draw an optimal resection 
line quite challenging. There is a high risk o f there being too little function in the 
hepatic remnant, leading to new problems. High rates of morbidity (37.5-67%) and 
mortality (3-11%) are reported.2 With the ultimate solution of liver transplantation 
in sight for the patient, resection is unfavourable because of the possible creation of 
dense adhesions.2’7 Postoperative complications are common and today experience 
of resection is declining with fewer surgeons favouring this approach. The authors 
believe that partial liver resection should never be the first choice but, if a patient has 
a premalignant liver disease or is unsuited for transplantation, and if fenestration is 
not possible, partial resection may be the only option for symptom relief.
Liver transplantation
The only curative therapeutic option for patients with a severe polycystic liver is liver 
transplantation. In Europe a total of 584 liver transplantations have been performed 
for polycystic liver. The 5-year survival rate o f 84% for this indication is higher than 
the overall patient survival rate for liver transplantation generally.9 Transplantation, 
however, is indicated in only a small minority o f patients with disabling symptoms 
and a greatly decreased quality of life.2 Although liver synthesis capacity may be 
near normal, malnutrition is the most important criterion in this context. Severe 
malnutrition adversely affects the outcome of transplantation, and so it is better to list 
patients at an earlier stage o f disease. As patients have no chance of receiving a donor 
liver if allocation is made by strict application of the Model for End-Stage Liver 
Disease (MELD) criteria, countries using M ELD include exceptions for patients 
with polycystic liver.
132 | Chapter 10
N on-in v a siv e  t h e r a p e u t ic  o p tio n s
At present, there are no viable therapeutic options for every single patient with a 
polycystic liver. All procedures are invasive and have their share of concomitant 
morbidity and mortality and the majority are palliative in nature. Therefore, there is 
a demand for other new treatment strategies, especially drug therapy.
The development and growth of cysts is promoted by enhanced fluid secretion, 
extracellular matrix remodelling and hyperproliferation of the lining epithelial cells.10 
The identification of pathways involved in this cyst development and growth, makes it 
possible to identify novel potential targets that might interfere with growth-promoting 
effects. Several pathways and interfering products as treatment for polycystic kidneys 
or livers have been studied in experimental models.
Cyclic adenosine monophosphate (cAMP)
The second messenger 3’-5’-cyclic adenosine monophosphate (cAMP) is a key 
intracellular mediator of biliary epithelial cell secretion and proliferation. In a rodent 
model for polycystic liver, the polycystic kidney (PCK) rat, elevated intracellular 
cAMP levels are associated with biliary epithelial cell hyperproliferation and cyst 
expansion.11 These elevated cAMP levels will activate Protein Kinase A (PKA) and 
Exchange Protein directly Activated by cAMP (Epac).12 The effect of Epac and PKA 
occur via the M EK /ER K 1/2 pathway, which will result in hyperproliferation (Figure 
10.2A). The administration of secretin increases the intracellular levels of cAMP by 
activation of adenylate cyclase (AC), which converts adenosine triphosphate into 
cAMP.13;14 This increase of cAMP stimulates exocytosis.15 Several medical targets 
might down-regulate this pathway and have been tested in different studies.
In view of the minimization of ascites development, patients were treated with H2- 
blockers,16;17 and octreotide, a somatostatin analogue.17’18 H2-blockers reduce the 
production of gastric acid. As the production of gastric acid is stimulated by the 
release of secretin, the reduced production of gastric acid might reduce the release 
o f secretin and this might minimize the development of ascites as well. None of the 
studies included a control group. Therefore, there is no evidence for H2-blockers in 
the treatment of ascites or liver cysts. In the same vein, there might be an argument 
for the use of more intense acid inhibitors such as the proton-pump-inhibitors. This 
class o f drugs has not been studied for this indication, though there are patients who 
report a beneficial effect.
By binding to a somatostatin receptor (SSTR 1-5), somatostatin and its analogues 
such as octreotide and lanreotide, activate signaling cascades through the inhibitory 
G (Gi) protein, which selectively gives reduced action of adenylate cyclase and as a 
result lower cAMP levels (Figure 10.2B). Somatostatin receptors are present on the 
cholangiocyte and rodent liver cystic epithelium.11’19 The treatment o f patients with
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Figure 10.2 Schematic overview of pathways involved in cell proliferation and fluid 
secretion of cystic epithelia cells in polycystic livers
Panel A g iv e s  th e  norm al situation . Panel B sh ow s th e  action  o f so m a to sta tin  and  mTOR inhibitors.
octreotide after extensive fenestration and resection demonstrated a beneficial effect 
through the control o f ascites.17 The lack of a control group in this study does not 
allow to provide definitive proof of efficacy of the use o f somatostatin analogues. 
First evidence for the role of somatostatin analogues in reducing intracellular cAMP 
levels and kidney and hepatic cystogenesis, has been demonstrated in vitro and in PCK 
rats.11 These effects were time- and dose-dependent. The treatment with somatostatin 
analogues in two patients with polycystic livers resulted in an impressive reduction of 
liver volume of 38 and 15%.20 An additional case series of eight patients treated with 
octreotide three times daily confirmed this observation, and also established that the 
effect could be reversed by stopping treatment. Final proof for the beneficial effect 
of somatostatin analogues comes from a randomized clinical trial with long-acting 
lanreotide. This randomized, double-blind, placebo-controlled trial demonstrated 
that 6-month treatment with lanreotide 120 mg once monthly resulted in a median 
liver volume reduction of 2.9%, compared to an increase o f 1.6% of liver volume in 
patients on placebo. Furthermore, kidney volume decreased with 1.5% in patients 
treated with lanreotide, while patients on placebo had an increase o f kidney volume 
of 3.4%. Side-effects of somatostatin-analogues were limited.21 
There are no data available upon the effect of longer duration of treatment. Furthermore,
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we observed one case where regrowth of cysts occurred after termination of treatment. 
The studies with somatostatin analogues show that medical therapy is possible, but 
before application of somatostatin analogues for the use in the treatment of polycystic 
livers in clinical practice, further trials must be performed to optimize dosage and 
treatment duration.
Tannic acid, which is a hydrolysable plant polyphenol present in a variety o f foods 
such as nuts, red wine, tea and coffee, appears to have an antiproliferative effect on 
cholangiocyte proliferation in vivo by lowering intracellular cAMP levels.22 Whether 
this antiproliferative effect applies for hepatic cyst epithelium has not been studied.
M ammalian target of rapamycin (mTOR)
Another mechanism which plays a role in the renal and hepatic cystogenesis is the 
mammalian target of rapamycin (mTOR). This pathway is highly activated in cyst lining 
epithelial cells o f patients with polycystic livers. Activated mTOR phosphorylates 
the 70 kDa ribosomal protein S6 kinase (S6K), which leads to enhanced protein 
synthesis and cell proliferation. Therefore, mTOR activation leads to biliary epithelial 
cell hyperproliferation (Figure 10.2A).23
The activation of mTOR can be reduced by mTOR inhibitors, such as sirolimus and 
everolimus (Figure 10.2B). The cyst reducing effect has been studied in a patient­
control study of ADPKD patients. After renal transplantation, these patients 
participated in a randomized trial comparing sirolimus with tacrolimus as part of 
their immunosuppressive regimen. The growth of the native polycystic kidneys was 
inhibited in the sirolimus group, but not in patients on tacrolimus. Furthermore, 
sirolimus also strongly reduced the growth of hepatic cysts in ADPKD patients.23 
Contrary to somatostatin-analogues, mTOR inhibitors have been associated with 
severe side-effects, such as leucopenia, hypercholesterolemia, infections, sepsis, 
thrombocytopenia, anaemia and nephrotoxicity. These adverse events make the role 
o f mTOR inhibitors in the treatment o f polycystic livers less attractive. However, a 
recent study with sirolimus as treatment o f polycystic kidneys in ADPKD patients 
described only mild side effects.24 In this respect, the role o f a combined therapy of 
somatostatin analogues and mTOR inhibitors to achieve synergistic volume reducing 
effect is of great interest.
C o n clu sio n
Polycystic liver is mainly a benign disease, but in a substantial minority of patients, 
disabling symptoms require various interventional treatments and even liver 
transplantation in the most severe cases. Treatment is currently based on invasive 
therapeutic options, but non-invasive therapeutic options are in sight.
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This thesis describes studies on the treatment o f polycystic livers. Polycystic livers 
are characterized by the presence of numerous cysts scattered throughout the whole 
liver parenchyma. This phenotype occurs in the setting of two inherited diseases: 
either in combination with polycystic kidneys: autosomal dominant polycystic kidney 
disease (ADPKD); or in an isolated form: autosomal dominant polycystic liver disease 
(PCLD).
The main aim of this thesis is to evaluate the available therapeutic options for polycystic 
livers in terms of effect o f treatment and best treatment strategy. Furthermore, 
identification of new non-invasive treatment was studied.
In the first part ‘Phenotype’, the clinical characterization of PCLD is described. Chapter 
2 gives the characterization of the largest cohort in literature of patients with PCLD. 
The majority of patients is female, median age at diagnosis is 47 years and 41% of the 
patients has a mutation in either PRKCSH  or SEC63. Gamma glutamyl transferase 
was elevated in 51% of the patients. Female patients and patients with a mutation 
were younger at diagnosis and more were symptomatic, compared to male and 
wildtype patients, respectively. In total, 58% of the patients were treated and 16 (14%) 
patients had an indication for liver transplantation. Five years after diagnosis, 44% 
of the patients with PCLD were treated. We found that 10% of untreated patients, 
developed a complication, whilst this was the case in 51% of treated patients. Only 
2% of the patients died due to complications from their treatment o f PCLD.
In the second part o f this thesis, ‘Invasive therapeutic options’, the various invasive 
options, were studied, starting with aspiration-sclerotherapy in chapter 3. Aspiration- 
sclerotherapy is the less invasive therapeutic option for treating patients with 
polycystic livers and with single liver cysts. We observed a liver volume reduction of 
19% in patients with a polycystic liver and 17% in patients with a large single liver 
cysts. Furthermore, the severity o f symptoms decreased, although four patients were 
referred for laparoscopic fenestration. Patients with liver cysts larger than 5 cm are 
most suitable for this procedure.
Laparoscopic fenestration is a more invasive therapeutic option. In chapter 4, twelve 
patients were treated with laparoscopic fenestration and a median volume reduction 
of 12.5% was achieved with concomitant decrease o f the severity o f symptoms. 
Unfortunately, the morbidity was 25%. Patients with fairly large, well-accessiblecysts 
are particularly suitable for laparoscopic fenestration.
We also commented on a large study on hepatic resection of polycystic livers. The 
authors o f this study advocate the use of this procedure in patients with a polycystic 
liver, although the procedure is associated with significant morbidity. In chapter
5 we described our concerns regarding the limited experience with the procedure 
that is currently available, even in tertiary referral centers, the high morbidity rates 
and the risk of adhesions, which could be unfavourable factors for a future liver
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transplantation.
Liver transplantation is the only curative treatment for patients with a polycystic 
liver. Chapter 6 brings together the data of a large cohort of patients with PCLD 
who underwent liver transplantation. The 1-year and 5-year patient survival rates are 
94.8% and 92.3%, respectively. These survival rates did not differ from patients with 
ADPKD and are much better than for patients who underwent a liver transplantation 
for a different indication.
The third part ‘Non-invasive therapeutic options’, starts with the first observations of 
medical treatment in polycystic liver patients. The two patients in chapter 7 were 
treated with somatostatin analogues, which resulted in a liver volume reduction of 
38.3% and 14.9%.
Treatment with octreotide 100 ^g three times daily subcutaneous resulted in a 
median volume reduction of 3% in 8 patients (chapter 8). No volume reduction of 
the polycystic kidneys was observed.
Chapter 9 focuses on the LOCKCYST trial. This is a randomized, double-blind, 
placebo-controlled trial to study the effect of lanreotide 120 mg monthly in patients 
with a polycystic liver. The treatment with lanreotide during six months resulted in 
a liver volume reduction of 2.9% and kidney volume reduction of 1.5%, instead of 
an increase of liver volume of 1.6% and an increase o f kidney volume of 3.6%. In 
addition, patients treated with lanreotide had an increase of current health perception, 
which did not apply to patients on placebo.
Finally, in the last part of this thesis ‘Callfor a Yielding Single Treatment Strategy’ in 
chapter 10, all invasive therapeutic options are reviewed and the current knowledge 
on non-invasive therapeutic options are described. In addition, we give a flow chart 
for the various treatment options.
Future perspectives
The studies on non-invasive therapeutic options are limited and further study is 
needed to introduce this treatment into daily clinical practice. We studied the effect 
o f lanreotide 120 mg once monthly for six months and observed a reduction in 
polycystic liver and polycystic kidney volume. Whether this is effect is maintained 
with prolonged treatment is worth studying. Furthermore, we chose for the highest 
dosage of 120 mg, but we do not know whether this is the optimal dosage or if lower 
dosages could give the same effect. We treated a series of patients with octreotide 100 
|ag three times daily and observed a volume reducing effect on the polycystic liver, but 
not on the polycystic kidneys. The effect of somatostatin analogues, short-acting or 
long-acting, should be studied in more depth to assess the most optimal dosage and 
duration of treatment.
At this point in time, somatostatin analogues seem to be able to alter the natural 
course of the disease (growth of liver volume) and establish liver volume reduction.
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Although this effect is even better than slowing growth, the effect might be improved 
with additional drug treatment. Inhibitors o f mTOR can be such an alternative option, 
as a study demonstrated a liver volume reducing effect of sirolimus. Besides the effect 
on liver and kidney volume, an important issue which should be studied is the safety 
of these drugs. The adverse effects of these drugs are serious and might influence 
the health status of the patients. Apart from their polycystic liver, the majority of the 
patients are healthy and the safety profile o f this class of drugs is an important issue 
in the design of new trials.
Apart from optimalizing non-invasive therapeutic options, we may improve the 
outcome of invasive options by combining them with effective drugs. The start of 
treatment with somatostatin analogues directly after an invasive treatment may result 
in a prolonged palliative effect of the treatment. This leads to a number of important 
questions. What would be the effects of leaving somatostatin analogues in the cyst 
after aspiration-sclerotherapy? And does this improve the results? And after cyst 
fenestration, are somatostatin analogues able to slow down or even avoid recurrence 
of the cysts?
In conclusion, we may state that there is still a long way to go, but our efforts have 
opened the door to a non-surgical approach of the patient with polycystic liver. We 
do not know where this road is going to lead us, but there is hope that we will find 
the answers our patients are waiting for.
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Dit proefschrift beschrijft een onderzoek over de behandeling van polycysteuze 
levers. Polycysteuze levers worden gekenmerkt door de aanwezigheid van talrijke 
cysten verspreid over het hele leverparenchym. Dit ziektebeeld komt voor bij twee 
erfelijke ziekten: ofwel in combinatie met polycysteuze nieren, wat autosomaal 
dominant polycysteuze nierziekte (ADPKD) wordt genoemd, ofwel in een geïsoleerde 
vorm, wat autosomaal dominante polycysteuze leverziekte (PCLD) wordt genoemd. 
Het belangrijkste doel van dit proefschrift was om de beschikbare therapeutische 
opties voor polycysteuze levers te beoordelen in termen van effectiviteit en tot een 
behandelstrategie te komen. Daarnaast werd een nieuwe niet-invasieve behandeling 
onderzocht.
In het eerste deel ‘Fenotype’, wordt de klinische karakterisering van PCLD beschreven. 
Hoofdstuk 2 beschrijft de grootste groep patiënten met PCLD, die tot nu toe in 
de literatuur beschreven is. De meerderheid van de patiënten is vrouw, de mediane 
leeftijd bij diagnose is 47 jaar en 41% van de patiënten heeft een mutatie in een van 
beide genen PRKCSH  o f SEC63. Gamma glutamyl transferase was verhoogd in 51% 
van de patiënten. Vrouwelijke patiënten en patiënten met een mutatie waren jonger 
bij diagnose en meer symptomatisch dan mannelijke patiënten en patiënten zonder 
mutatie. In totaal werd 58% van de patiënten behandeld. Zestien (14%) patiënten 
hadden een indicatie voor levertransplantatie. Vijf jaar na diagnose was 44% van 
de patiënten met PCLD behandeld. We ontdekten dat 10% van de onbehandelde 
patiënten een complicatie ontwikkelden, terwijl dat bij 51% het geval was van de 
behandelde patiënten. Slechts 2% van de patiënten is overleden als gevolg van een 
complicatie van de behandeling van PCLD.
In het tweede deel van dit proefschrift, ‘Invasieve therapeutische opties’, worden de 
verschillende invasieve opties beschreven, te beginnen met aspiratie-sclerotherapie 
in hoofdstuk 3. Aspiratie-sclerotherapie is de minst invasieve behandelmethode 
voor patiënten met polycysteuze levers en met een enkele levercyste. We zagen een 
vermindering van het levervolume van 19% bij patiënten met een polycysteuze lever 
en 17% bij patiënten met een grote enkele levercyste. Bovendien verminderde de ernst 
van de symptomen, maar toch werden vier patiënten verwezen voor laparoscopische 
fenestration. Patiënten met levercysten, die groter dan 5 cm zijn, bleken het meest 
geschikt voor deze methode.
Laparoscopische fenestration is een meer invasieve behandelmethode. In hoofdstuk 
4 worden de resultaten van twaalf patiënten beschreven die een laparoscopische 
fenestration ondergingen. Er werd een mediane volume vermindering van 12,5% 
bereikt met gelijktijdige vermindering van de ernst van de symptomen. Echter, de 
morbiditeit was 25%. Patiënten met vrij grote en makkelijk middels laparoscopie te 
bereiken cysten bleken vooral geschikt voor laparoscopische fenestration.
Daarnaast hebben we gereageerd op een grote studie, die leverresectie van
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polycysteuze levers beschrijft. De auteurs van deze studie pleiten voor het gebruik 
van deze procedure bij patiënten met een polycysteuze lever. Toch is kent deze 
procedure een significante morbiditeit. In hoofdstuk 5 beschreven we onze zorgen 
over de beperkte ervaring van deze behandeling die momenteel beschikbaar. Zelfs 
in de tertiaire verwijzing centra, de hoge morbiditeit en het risico op adhesies, wat 
ongunstige factoren zouden kunnen zijn voor een toekomstige levertransplantatie. 
Levertransplantatie is de enige behandeling die patiënten met een polycysteuze lever 
kan genezen. Hoofdstuk 6 beschrijft de gegevens van een grote groep patiënten met 
PCLD die een levertransplantatie onderging. De 1-jaars en 5-jaars patiëntenoverleving 
is respectievelijk 94,8% en 92,3%. Deze overleving verschilde niet van patiënten met 
ADPKD en zijn veel beter dan patiënten die een levertransplantatie ondergingen 
voor een andere indicatie.
Het derde deel ‘Niet-invasieve therapeutische opties’, begint met de eerste resultaten van 
medicamenteuze behandeling van patiënten met een polycysteuze lever. De twee 
patiënten in hoofdstuk 7 werden behandeld met somatostatine-analogen, wat 
resulteerde in een vermindering van het levervolume met 38,3% en 14,9%. 
Behandeling met octreotide 100 ^g driemaal daags subcutaan resulteerde in een 
mediane volume vermindering van 3% in 8 patiënten (hoofdstuk 8). Er werd geen 
volumevermindering van de polycysteuze nieren waargenomen.
Hoofdstuk 9 richt zich op de LOCKCYST studie. Dit was een gerandomiseerde, 
dubbelblinde, placebo-gecontroleerde studie naar het effect van lanreotide 120 mg 
maandelijks bij patiënten met een polycysteuze lever. De behandeling met lanreotide 
gedurende zes maanden resulteerde in een vermindering van het levervolume met 
2,9% en het niervolume verminderde met 1,5%, in plaats van een toename van het 
levervolume met 1,6% en het niervolume met 3,6%. Bovendien was er een toename 
van de beoordeling van de gezondheid in de groep van patiënten die met lanreotide 
werd behandeld, terwijl dit niet gold voor patiënten die placebo kregen.
Tot slot, het laatste deel van dit proefschrift “Callfor a Yielding Single Treatment Strategy”. 
In hoofdstuk 10 worden alle invasieve therapeutische opties en de huidige kennis 
van niet-invasieve therapeutische mogelijkheden beschreven. Daarnaast geven we 
een stroomdiagram voor de verschillende mogelijke behandelingopties.
Toekomstperspectieven
Studies naar niet-invasieve therapeutische mogelijkheden zijn beperkt en verder 
onderzoek is nodig om deze behandelingen uit te voeren in de dagelijkse klinische 
praktijk. We bestudeerden het effect van lanreotide 120 mg eens per maand voor een 
duur van zes maanden en zagen een afname van het polycysteuze lever- en polycysteuze 
niervolume. O f dit effect wordt behouden met een langdurige behandeling moet 
worden bestudeerd. Verder kozen we voor de hoogste dosering van 120 mg, maar 
we weten niet of dit de optimale dosering was o f dat een lagere dosering hetzelfde
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effect kan geven. Wij behandelden een reeks van patiënten met octreotide 100 
driemaal daags en observeerden een afname van het volume van de polycysteuze 
lever, maar niet van de polycysteuze nieren. Het effect van somatostatine analogen, 
kortwerkend dan wel langwerkend, moet verder worden onderzocht om de meest 
optimale dosering en duur van de behandeling te kunnen vaststellen.
Op dit moment lijken somatostatine-analogen in staat om het natuurlijke beloop 
van de ziekte (groei van het levervolume) te veranderen en te zorgen voor een 
vermindering van het levervolume. Hoewel dit effect nog beter is dan een vertraagde 
groei, kan het effect mogelijk worden vergroot wanneer er andere medicijnen aan 
de behandeling worden toegevoegd. mTOR-remmers zijn een dergelijke alternatieve 
optie, wat in een studie naar het effect van sirolimus op het polycysteuze levervolume 
werd aangetoond. Naast het effect op het lever- en niervolume is het belangrijk de 
veiligheid van deze geneesmiddelen goed te bestuderen. De nadelige effecten van 
deze medicijnen kunnen ernstig en van invloed op de gezondheidstoestand van 
de patiënten zijn. Naast de polycysteuze lever is de meerderheid van de patiënten 
gezond en het veiligheidsprofiel van deze groep van geneesmiddelen is een belangrijk 
onderwerp in het ontwerp van nieuwe studies.
Naast het optimaliseren van niet-invasieve therapeutische opties, zouden we 
het resultaat van invasieve opties kunnen verbeteren door deze te combinateren 
met medicijnen. Het starten van somatostatine-analogen direct na een invasieve 
behandeling kan mogelijk leiden tot een langduriger palliatief effect van de 
behandeling. Dit leidt tot een aantal belangrijk vragen als: wat zou het resultaat 
zijn wanneer men na aspiratie-sclerotherapie somatostatine-analogen in de cyste 
achterlaat? En vergroot dit het resultaat van de behandeling? Zou de behandeling met 
somatostatine-analogen direct na laparoscopische fenestratie de groei van de cysten 
kunnen vertragen of zelfs voorkomen?
Concluderend is er nog steeds een lange weg te gaan, maar onze inspanningen hebben 
de ervoor gezorgd dat de deur is geopend voor een niet-chirurgische behandeling van 
de patiënt met een polycysteuze lever. We weten niet waar de weg ons zal leiden, maar 
er is hoop dat we antwoorden vinden waar onze patiënten op wachten.
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158 |
Dankwoord | 159
Esmé,MichelleenBjorn,mijnkamergenootjes,zonderjulliezoudendeafgelopenjarenniet 
zo leuk geweest zijn. Het was ergleuk en gezellig om met jullie de kamer te delen en te brain­
stormen en discussiëren over onderzoek... en vakantie, huizen, sporten, mandarijnen... 
Esmé en Michelle, ik vind het erg fijn dat jullie vandaag naast mij staan! En Esmé, 
heel erg bedankt voor het lay-outen van dit proefschrift!
De PCLD-onderzoeksgroep, Esmé, Jannes, Manoe en René onder leiding van Joost. 
Een leuke groep om mee samen te werken. Ik heb veel van jullie geleerd op het gebied 
van basaal onderzoek.
De medewerkers van lab MDL, Wilbert, Wim, René, Hennie, Annie, Marloes, Esmé, 
Bjorn, Michelle, Jannes en Manoe en alle stagiares, ik was een beetje een vreemde 
eend in de bijt, omdat ik eigenlijk helemaal geen labwerk deed. Ondanks dat waren 
jullie bereid om mee te denken over mijn onderzoek. Daarnaast ook bedankt voor de 
ontspanning tijdens de pauzes.
Alle stafleden en arts-assistent van de afdeling M DL, bedankt voor alles wat ik van 
jullie voornamelijk op het klinische gebied geleerd heb.
De secretaresses van MDL, altijd gezellig om even een praatje te maken bij jullie. 
Bedankt voor alle telefoontjes die jullie aan mij hebben doorverbonden en andere 
secretariële bezigheden, die meestal even tussendoor konden.
De leden van de clinical PhD council (CPC), ik vond het erg leuk om met jullie aan de 
wieg van de CPC te staan. Ik hoop dat onze plannen op een korte termijn gerealiseerd 
kunnen gaan worden.
Rianne en Melissa, ik vond het heel erg leuk en leerzaam om jullie te begeleiden. 
Rianne, bedankt voor de hulp in de laatste maanden van mijn promotie. Melissa, 
ik vind het erg leuk dat jij met grote enthousiasme verder gaat met het klinische 
onderzoek van polycysteuze levers. Fijn dat de patiënten bij jou in goede handen zijn.
Annelies, Floor, Inge, Kim, Lotte en Tanja, wat een leuke vriendinnengroep! Bedankt 
voor jullie interesse en steun bij mijn onderzoek en nog belangrijker alle gezellige 
momenten die niks met onderzoek te maken hadden. Ik vond het erg leuk om jullie 
verhalen tijdens jullie coschappen te horen, ik hoop dat jullie nu naar die van mij 
willen luisteren!
Kim, Linda, Marloes en Stan, ook al zien we elkaar niet meer zo vaak, het is altijd erg 
gezellig om leuke dingen met elkaar te doen.
Marleen, Stijntje en Heleen, bedankt voor de gezelligheid tijdens de honderden 
kilometers, die we hebben (hard)gelopen.
Janine en Karolina, bedankt voor de steun tijdens mijn onderzoek en de vriendschap. 
Thank you so much for the nice design of this cover, Rachel!
160 I
Lydia en Kees, bedankt voor jullie vertrouwen in mij en ik hoop dat ik nog vaak bij 
jullie mag logeren.
Mieke, Bart en Pim ik kan me geen lievere zus en broers wensen! Mieke, ik ben erg 
blij als je weer in Nederland woont. Ruud en Karin, erg leuk om jullie als schoonbroer 
en —zus te hebben.
Lieve papa en mama, jullie zijn de liefste ouders van de wereld. Bedankt voor jullie 
onvoorwaardelijke steun en vertrouwen in alles wat ik wil en doe. Fijn dat jullie altijd 
voor mij klaar staan!
Loes
Nijmegen, 21 december 2009
